

# AGENDA REGULAR MEETING OF THE EL CAMINO HOSPITAL BOARD OF DIRECTORS

Wednesday, May 12, 2021 – 5:30pm

El Camino Hospital | 2500 Grant Road Mountain View, CA 94040

PURSUANT TO STATE OF CALIFORNIA EXECUTIVE ORDER N-29-20 DATED MARCH 18, 2020, EI CAMINO HEALTH **WILL NOT BE PROVIDING A PHYSICAL LOCATION FOR THIS MEETING**. INSTEAD, THE PUBLIC IS INVITED TO JOIN THE OPEN SESSION MEETING VIA TELECONFERENCE AT:

1-669-900-9128, MEETING CODE: 939-9780-1384#. No participant code. Just press #.

To watch the meeting livestream, please visit: <a href="https://www.elcaminohealth.org/about-us/leadership/board-meeting-stream">https://www.elcaminohealth.org/about-us/leadership/board-meeting-stream</a>
Please note that the livestream is for **meeting viewing only** and there is a slight delay; to provide public comment, please use the phone number listed above.

MISSION: To heal, relieve suffering, and advance wellness as your publicly accountable health partner.

|     | AGENDA ITEM   | PRESENTED BY   |                   | ESTIMATED<br>TIMES             |
|-----|---|--|-------------------|--------------------------------|
| 1.  | CALL TO ORDER/ROLL CALL   | Lanhee Chen, Board Chair   |                   | 5:30 – 5:31pm                  |
| 2.  | POTENTIAL CONFLICT OF INTEREST DISCLOSURES  | Lanhee Chen, Board Chair   |                   | information<br>5:31 – 5:32     |
| 3.  | PUBLIC COMMUNICATION  a. Oral Comments  This opportunity is provided for persons in the audience to make a brief statement, not to exceed three (3) minutes on issues or concerns not covered by the agenda.  b. Written Correspondence     | Lanhee Chen, Board Chair   |                   | information<br>5:32 -5:34      |
| 4.  | QUALITY COMMITTEE REPORT ATTACHMENT 4   | Julie Kliger, Quality<br>Committee Chair;<br>Mark Adams, MD, CMO | public<br>comment | motion required<br>5:34 – 5:44 |
| 5.  | BOARD OFFICERS NOMINATION AND SELECTION PROCEDURES FOR FY21 ATTACHMENT 5  | Lanhee Chen, Board Chair   | public<br>comment | motion required<br>5:44 – 5:46 |
| 6.  | BOARD OFFICER ELECTIONS <u>ATTACHMENT 6</u>   | Lanhee Chen, Board Chair   | public<br>comment | motion required<br>5:46 – 6:06 |
| 7.  | FY21 PERIOD 9 FINANCIALS  ATTACHMENT 7  | Carlos Bohorquez, CFO  | public<br>comment | possible motion<br>6:06 – 6:16 |
| 8.  | ADJOURN TO CLOSED SESSION   | Lanhee Chen, Board Chair   | public<br>comment | motion required<br>6:16 – 6:17 |
| 9.  | POTENTIAL CONFLICT OF INTEREST DISCLOSURES  | Lanhee Chen, Board Chair   |                   | information<br>6:17 – 6:18     |
| 10. | CONSENT CALENDAR  Any Board Member may remove an item for discussion before a motion is made.   | Lanhee Chen, Board Chair   |                   | motion required<br>6:18 – 6:21 |
|     | <ul> <li>Approval</li> <li>Gov't Code Section 54957.2:</li> <li>a. Minutes of the Closed Session of the Hospital Board Meeting (04/07/2021)</li> <li>b. Minutes of the Closed Session of the Hospital Board Meeting (04/14/2021)</li> </ul> |  |                   |                                |

A copy of the agenda for the Regular Board Meeting will be posted and distributed at least seventy two (72) hours prior to the meeting. In observance of the Americans with Disabilities Act, please notify us at (650) 988-7504 prior to the meeting so that we may provide the agenda in alternative formats or make disability-related modifications and accommodations.

Agenda: ECH Board | Regular Meeting May 12, 2021 | Page 2

|     | AGENDA ITEM   | PRESENTED BY                               |                   | ESTIMATED<br>TIMES          |
|-----|---|--|-------------------|-----------------------------|
|     | <ul> <li>c. Minutes of the Closed Session of the Hospital Board Meeting (04/28/2021)</li> <li>Reviewed and Recommended for Approval by the Quality, Patient Care and Patient Experience</li> <li>Committee</li> <li>Health &amp; Safety Code Section 32155 for a report of the Medical Staff; deliberations concerning reports on Medical Staff quality assurance matters:</li> <li>d. Quality Committee Report <ul> <li>(i) Medical Staff Credentials and Privileges Report</li> <li>(ii) Quality Council Minutes</li> </ul> </li> </ul> |  |                   |                             |
| 11. | Health And Safety Code Section 32106(b) for a report and discussion involving health care facility trade secrets: - Semi-Annual ECHMN Report  | Vince Manoogian, SVMD<br>Interim President |                   | discussion<br>6:21 – 6:41   |
| 12. | <ul> <li>Health and Safety Code Section 32106(b) for a report and discussion involving health care facility trade secrets:</li> <li>FY21 Strategic Plan Q3 Metrics Update &amp; Draft FY22 Strategic Plans And Goals</li> </ul>   | Dan Woods, CEO                             |                   | discussion<br>6:41 – 6:51   |
| 13. | Health and Safety Code Section 32106(b) for a report and discussion involving health care facility trade secrets - FY22 Budget Preview (Assumptions)  | Carlos Bohorquez, CFO                      |                   | discussion<br>6:51 – 7:21   |
| 14. | Gov't Code Section 54956.9(d)(2) – conference with legal counsel – pending or threatened litigation; Gov't Code Section 54957 and 54957.6 for discussion and report on personnel matters:  - CEO Report on Legal Update and Personnel Matters   | Dan Woods, CEO                             |                   | discussion<br>7:21 – 7:26   |
| 15. | Report involving <i>Gov't Code Section 54957</i> for discussion and report on personnel performance matters – Senior Management:  - Executive Session   | Lanhee Chen, Board Chair                   |                   | discussion<br>7:26 – 7:36   |
| 16. | ADJOURN TO OPEN SESSION   | Lanhee Chen, Board Chair                   |                   | motion required 7:36 – 7:37 |
| 17. | RECONVENE OPEN SESSION/ REPORT OUT  To report any required disclosures regarding permissible actions taken during Closed Session.   | Lanhee Chen, Board Chair                   |                   | information<br>7:37 – 7:38  |
| 18. | CONSENT CALENDAR ITEMS: Any Board Member or member of the public may remove an item for discussion before a motion is made.   | Lanhee Chen, Board Chair                   | public<br>comment | motion required 7:38 – 7:43 |

Agenda: ECH Board | Regular Meeting

May 12, 2021 | Page 3

|     | AGENDA ITEM  | PRESENTED BY             |                   | ESTIMATED<br>TIMES             |
|-----|--|--------------------------|-------------------|--------------------------------|
|     | a. Hospital Board Minutes (04/7/21) Open Session Minutes b. Hospital Board Minutes (04/14/21) Open Session Minutes c. Hospital Board Minutes (04/28/21) Open Session Minutes  Reviewed and Recommended for Approval by the Finance Committee d. FY21 Period 8 Financials  Reviewed and Recommended for Approval by the Medical Executive Committee e. Medical Staff Report |                          |                   |                                |
| 19. | CEO REPORT ATTACHMENT 19   | Dan Woods, CEO           |                   | information<br>7:43 – 7:48     |
| 20. | BOARD COMMENTS   | Lanhee Chen, Board Chair |                   | information<br>7:48 – 7:51     |
| 21. | ADJOURNMENT  | Lanhee Chen, Board Chair | public<br>comment | motion required 7:51 – 7:52 pm |

Upcoming Regular Meetings: May 24, 2021 (Joint with Finance Committee); June 9, 2021



#### EL CAMINO HOSPITAL BOARD OF DIRECTORS BOARD MEETING MEMO

**To:** El Camino Hospital Board of Directors

From: Julie Kliger, MPA, BSN, Quality Committee Chair

Mark Adams, MD, CMO

**Date:** May 12, 2021

**Subject:** Quality, Patient Care and Patient Experience Committee Report

**Purpose:** To inform the Board of the work of the Quality Committee.

#### **Summary:**

- 1. Cheryl Reinking RN, CNO, presented a patient story involving a complaint on two counts. One, the treating anesthesiologist did not communicate very well regarding the planned procedure for the delivery. The second issue was the lack of a pediatrician at the bedside for the delivery. Regarding the first issue, physicians are now required to have six core competencies, one of which is interpersonal communication skills. This is an area that needs to be improved for this particular physician and this will be addressed. Regarding the second issue, for normal uncomplicated deliveries it is not standard practice to have an attending pediatrician. There is a requirement for a pediatrician well baby check-up within 24 hours of birth which we do provide. A committee member suggested that the patients be better informed about that.
- 2. Mark Adams MD, CMO, presented the proposed organizational strategic goals pertaining to quality, safety, and patient experience. After discussion, the committee approved recommending to the Board adoption of the following goals:
  - **a.** <u>Serious Safety Event Rate (SSER):</u> This is a measure of high reliability (HRO) and continues from FY21. This aligns with our true north quality pillar of zero preventable harm.
  - **b.** Readmission Index: This reflects our ability to provide a continuity of care; can be influenced by many parts of the organization including ambulatory (SVMD); affects our Medicare Readmission Penalty Program score; affects our CMS Bundled Payment for Clinical Improvement-Advanced success.
  - **c.** <u>HEDIS Composite:</u> This is a key indicator of quality in the ambulatory space and the components also contribute to payer ratings and MIPS scores.
  - d. <u>Likelihood to Recommend (LTR)</u>: This is a key metric analogous to the Net Promoter Score used by many industries to assess customer experience and to predict future growth.
- 3. The proposed FY22 quality committee agenda pacing plan was presented and approved by the committee.

- 4. Vince Manoogian, interim president of SVMD, provided a quarterly update on the current status of SVMD quality and experience results. The HEDIS composite score decreased slightly to 3.2. The measures needing further improvement were reviewed. The results for the CMS MIPS program have been submitted with all indications being that this will result in an exceptional rating for SVMD which will earn a financial bonus payment from Medicare. There was an extensive discussion following the presentation on the current state and plans for improvement within SVMD.
- 5. Mark Adams then reviewed the quarterly Board quality dashboard for Q3. The following information was provided to elaborate on the areas currently below target:

#### a. Safe Care:

- Mortality index has increased in this quarter with two main drivers noted: COVID-19 patient deaths and advanced sepsis patient deaths refractory to sepsis treatment. 54% of all deaths were attributable to sepsis with 38% of deaths occurring within 48 hours of admission.
- ii. Sepsis mortality index has increased significantly despite improved SEP-1 compliance. The findings of 38% of deaths within 48 hours suggests a higher incidence of end stage sepsis which can be refractory to the standard sepsis bundle application.
- iii. SSER is below target but the Precursor Safety Event numbers are still high.
- iv. C.Diff: 7 cases total; 1 in March which was a failed screening
- v. CLABSI: 2 total; one in LG and one in MV; both in oncology patients; the LG case breaks a greater than 3 year 0 CLABSI record for LG

#### b. Timely:

 All three ED measures showed increases related to increasing COVID census; combination of waiting for test results and delays because of bed availability. Within the measure there has been improvement in the consult to admit order subset.

#### c. Effective Care:

- i. Readmission Index increased driven significantly by COVID-19 patients who showed a selective index of 1.40.
- ii. CMS SEP-1 Compliance rate: slight decrease in Q3 to 80.5% but still below internal goal of 86%; (CMS median rate is 60% across all hospitals)
- iii. PC-02 C/S rate: increased again primarily driven by a doubling of the rate in LG and several outlier obstetricians; effect of increased elective inductions being studied.
- d. Efficient Care: No issues
- e. Equitable Care: No issues
- f. Patient-Centered Care:
  - i. IP enterprise improved but below target. ED slightly decreased, MCH improved but below target, outpatient surgery stable but below target. Visitation as a factor has lessened as some visitation is now permitted. Enhanced patient rounding is being ramped up.

**Attachments:** Quarterly Board Quality Dashboard Q3



#### Quarterly Board Quality Dashboard (STEEEP Dashboard) FYTD 21, Q3 (unless otherwise specified by \*)

| O Phys.              |   | Baseline        | Target    |                 |                                      | Performance     |       |              |
|----------------------|---|-----------------|-----------|-----------------|--------------------------------------|-----------------|-------|--------------|
| Quality<br>Domain    | Metric  | FY 20           | FY 21     | FY21,           | FY21,                                | FY21,           | FY21, | FYTD21 Total |
|                      |   | F1 20           |           | Q1              | Q2                                   | Q3              | Q4    | FIIDZI Total |
|                      | Risk Adjusted Mortality Index                                 | 0.74            | 0.76      | 0.75            | 0.79                                 | 1.05            |       | 0.87         |
|                      | Sepsis Mortality Index  | 0.96            | 0.90      | 0.76            | 1.14                                 | 1.29            |       | 1.08         |
| Care                 | Serious Safety Events Rate (SSER) (baseline Dec'19 to Jun'20) | 4.28            | 4.00      | 3.98            | 3.35                                 | 3.54            |       | 3.54         |
| පී                   | Surgical Site Infections (SSI)                                | 0.36            | 1.0 (SIR) | 0.62            | 0.11                                 | 0.23            |       | 0.33         |
| Safe                 | Catheter Associated Urinary Tract Infection (CAUTI) - HAI     | 0.47            | <= 0.48   | 0.51            | 0.71                                 | 0.00            |       | 0.4          |
| Š                    | Central Line Associated Blood Stream Infection (CLABSI) - HAI | 0.15            | <= 0.2    | 0.0             | 0.71                                 | 0.82            |       | 0.7          |
|                      | Clostridium Difficile Infection (CDI) - HAI                   | 1.46            | <= 1.46   | 1.6             | 1.43                                 | 2.59            |       | 1.88         |
|                      | Modified PSI-90 CMS HAC Reduction Program                     | 0.919           | 0.90      | 0.898           | 0.815                                | 1.034           |       | 0.838        |
| <u>&gt;</u>          | Patient Throughput - ED Door to Admit Order                   | 190 min         | 181 min   | 188 min         | 195 min                              | 196 min         |       | 193.5 min    |
| Timely               | Patient Throughput - Median Time Arrival to ED Departure      | 284 min         | 245 min   | 255 min         | 274 min                              | 271 min         |       | 265 min      |
| F                    | ED Arrival to Direct Discharge for ED Patients                | 151 min         | 145 min   | 154 min         | 154 min                              | 162 min         |       | 156.5 min    |
|                      | Risk Adjusted Readmissions Index                              | 0.96            | 0.93      | 0.88            | 0.96                                 | *1.03           |       | 0.95         |
|                      | CMS SEP-1 Compliance Rate                                     | 70.9%           | 86%       | 67.6%           | 81.8%                                | 80.5%           |       | 77.3%        |
| <u>ĕ</u> .           | PC-01 Elective Delivery Prior to 39 Weeks Gestation           | ENT: 1.3%       | 1.3%      | 0% (0/70)       | 1.2% (1/85)                          | *0% (0/60)      |       | 0.47%        |
| ಜ                    | PC-02 NTSV C-Section  | ENT: 24.0%      | 23.5%     | 27.6% (142/514) | 25.8% (120/466)                      | *27.6% (81/294) |       | 26.9%        |
| Effective            | ECMN: CMS 165 Controlling High Blood Pressure                 | 51.20%          | <= 63%    | 58.0%           | 56.0%                                | 52.0%           |       | 57.0%        |
| _                    | ECMN: CMS 122 Diabetes Hemoglobin A1c Poor Control            | 43.30%          | <= 45     | 27.0%           | 29.0%                                | 45.0%           |       | 33.3%        |
|                      | HEDIS: Composite  | NA              | 3.0       | 3.3             | 3.3                                  | 3.2             |       | 3.25         |
| ient                 | Arithmetic Observed LOS/ Geometric Expected LOS               | 1.32            | 1.30      | 1.32            | 1.32                                 | 1.31            |       | 1.31         |
| Efficient            | MSPB-1 Medicare Spending per Beneficiary (CMS)                | 0.99<br>(CY 18) | 0.99      | 0.99            | None, updated annually<br>in January | 1.00            |       | 0.99         |
|                      | Hospital Charity Care Support                                 | \$20.5 mil      | NA        | \$6.6 mil       | \$5.7 mil                            | 7.4 mil         |       | \$19.7 mil   |
| e                    | Clinic Charity Care Support                                   | \$44.3k         | NA        | \$8.4k          | 1.1k                                 | 3.3k            |       | 12.9k        |
| Equitable            | Language Line Unmet Requests (data collection started Q2)     | 0.34%           | <1%       | 0.39%           | 0.64%                                | 1.07%           |       | 0.70%        |
| 듩                    | Length of Stay Disparity (Top 3 races)                        | Black: 4.05     |           | 3.98            | 4.56                                 | 4.11            |       | 4.13         |
| ш                    | 40% patients did not report their race                        | White: 3.79     | NA        | 3.81            | 3.97                                 | 3.92            |       | 3.93         |
|                      | 40% patients did not report their race                        | Asian: 3.64     |           | 3.54            | 3.38                                 | 3.72            |       | 3.52         |
|                      | IP Enterprise - HCAHPS Likelihood to Recommend                | 83.1            | 83.6      | 80.7            | 78.6                                 | 81.4            |       | 80.2         |
| Patient-<br>centered | ED - Likelihood to Recommend (PG)                             | 75.7            | 78.2      | 73.9            | 78.7                                 | 76.5            |       | 76.5         |
| tie                  | ECHMD - Likelihood to Recommend Care Provider (NPS)           | 73.2            | 75.7      | 76.2            | 76.0                                 | 76.4            |       | 76.1         |
| <u> </u>             | MCH - HCAHPS Likelihood to Recommend                          | 84.1            | 84.6      | 82.9            | 78.2                                 | 83.4            |       | 81.4         |
|                      | OAS - HCAHPS Likelihood to Recommend                          | 84.7            | 86.4      | 83.5            | 86.1                                 | 86.1            |       | 85.2         |

Report updated 4/23/21

STEEEP: Safe Care, Timely, Effective, Efficient, Equitable, Patient-Centered

<sup>\*</sup> data available up to FYTD 21 February only

<sup>\*\*</sup> data available FYTD 21 January only, displays rolling 12 month data (December 2019 to January 2021)



# **LEAPFROG SCORES**

El Camino Hospital (05-0308)

2500 Grant Road, Mountain View, CA 94040

My Score My Letter Grade

3.3125

El Camino Hospital Los Gatos (05-0308) 815 Pollard Road, Los Gatos, CA 95032

| My Score | My Letter Grade |
|----------|-----------------|
| 3.1291   | B               |

CMS Star Rating: Another 5 Star Score for El Camino

**April 2021** 

| Overall Star Rating Results | Your Hospital's Results  | National Average       |
|-----------------------------|--------------------------|------------------------|
| Overall Star Rating [a]     | ***** (5 out of 5 stars) | *** (3 out of 5 stars) |
| Hospital Summary Score [b]  | 0.52                     | -0.05                  |
| Peer Grouping [c]           | 5 Measure Groups         |                        |

Of the total 50 measures in the report, ECH's Measure results improved in many of them over the January 2020 report.

## Hospital Value-Based Purchasing: El Camino Hospital

FFY 2022 (effective 10/1/2021)

| Base Operating DRG | Withhold Amount/    | Bonus        | Net Impact | Estimated   |
|--------------------|---------------------|--------------|------------|-------------|
| Payments           | % of revenue -2.00% | Amount       | / 0.36%    | Total Score |
| \$102,827,559      | \$2,056,551         | \$ 2,431,563 | \$ 375,012 | 33.9 %      |

| Safety (25% of Total Performance So<br>Baseline period                              |                | Performance pe         | eriod          |
|---|----------------|------------------------|----------------|
| HAI: CY 2018  |                | HAI: CY 2020           |                |
| Description   | Threshold      | Performance/<br>Points | Benchmark      |
| Catheter-Associated Urinary Tract Infection   | 0.633          | 0.69/5                 | 0.000          |
| Central Line-Associated Blood Stream<br>Infection                                   | 0.727          | 0.28/6                 | 0.000          |
| Clostridium difficile Infection   | 0.646          | 0.43/4                 | 0.047          |
| Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia: HO LabID             | 0.748          | 1.33/0                 | 0.000          |
| Surgical Site Infection:<br>Colon Surgery (HAI 3)<br>Abdominal Hysterectomy (HAI 4) | 0.749<br>0.727 | 0.177/7<br>1.062/0     | 0.000<br>0.000 |
| Surgical Site Infection Composite   | N/A            | N/A                    | N/A            |

Infections are SIRs. Lower is better for all measures.

<sup>\*</sup>Threshold values will be modified when re-baseline data is released.

| Clinical Outcomes (25% of Total Performance Score) Domain Score = 63.33 |  |             |                        |             |
|---|--|-------------|------------------------|-------------|
| Baseline period   |  | Performanc  |                        | ce period   |
| Mort - 7/2012-6/20  | 015  |             | 9/1/2017-6             | /30/2020    |
| THA/TKA Complica  | ations - 4/1/2012-3/31/2015                                |             | 4/1/2017-3             | 3/3/2020    |
| Measure ID  | Description - Mortality Rate                               | Threshold % | Performance<br>/Points | Benchmark % |
| MORT-30-AMI   | Acute Myocardial Infarction<br>(AMI) 30-day mortality rate | 0.14        | 0.11/10                | 0.12        |
| MORT-30-HF  | Heart Failure (HF) 30-day mortality rate                   | 0.12        | 0.10/10                | 0.10        |
| MORT-30-PN  | Pneumonia (PN) 30-day mortality rate                       | 0.16        | 0.13/1                 | 0.13        |
| MORT-30-COPD COPD 30-day mortality rate                                 |  | 0.08        | 0.07/4                 | 0.06        |
| THA/TKA   | Primary THA/TKA complication rate                          | 0.03        | 0.03/6                 | 0.02        |
| MORT-30-CABG  | CABG 30-day mortality rate                                 | 0.03        | 0.03/7                 | 0.02        |

| 25%<br>Safety           | 25%<br>Patient<br>Experience<br>of Care |  |
|-------------------------|---|--|
| 25%<br>Clinical<br>Care | 25%<br>Efficiency Domain<br>Weighting   |  |

| Baseline period                    |                            | Performance peri | od            |
|------------------------------------|----------------------------|------------------|---------------|
| CY 2018                            |                            | CY 2020          |               |
| Description                        | Performance (%)/<br>Points | Threshold (%)    | Benchmark (%) |
| Communication with Nurses          | 80%/1                      | 79.18            | 87.53         |
| Communication with Doctors         | 82%/3                      | 79.72            | 87.85         |
| Responsiveness of Hospital Staff   | 65%/0                      | 65.95            | 81.29         |
| Communication about Medicines      | 66%/3                      | 63.59            | 74.31         |
| Hospital Cleanliness and Quietness | 67.5%/2                    | 65.46            | 79.41         |
| Discharge Information              | 86%/0                      | 87.12            | 91.95         |
| Care Transitions                   | 54%/2                      | 51.69            | 63.11         |
| Overall Rating of Hospital         | 79%/5                      | 71.37            | 85.18         |

Higher is better for all scores.


|  | Efficiency (25* of Total Performance Score) Domain Score = 10.0 |                                      |   |                        |  |
|--|---|--------------------------------------|---|------------------------|--|
|  | Baseline period CY 2018   |                                      |   | Performance period     |  |
|  |   |                                      | 2018 CY   |                        |  |
|  | Measure ID  | Description                          | Threshold   | Performance<br>/Points | Benchmark  |
|  | MSPB-1  | Medicare Spending<br>per Beneficiary | Median MSPB ratio<br>hospitals during<br>performance period<br>0.99 | 0.99/1                 | Mean of the lowest decile MSPB ratios for all hospitals during performance period – 0.85 |

Lower is better for all scores.

Adapted by Qualis Health from materials provided by Stratis Health and prepared under contract with the Centers for Medicare & Medicaid Services (CMS), and agency of the U.S. Department of Health and Human Services.


# IBM/Watson Health Top 100 Hospitals

### LARGE COMMUNITY HOSPITAL




# IBM/Watson Health Top 100 Hospitals

### MEDIUM COMMUNITY HOSPITAL




# IBM/Watson Health Top 100 Hospitals

### SMALL COMMUNITY HOSPITAL




# IBM/Watson Health Top 100 Hospitals



# IBM/Watson Health Top 100 Hospitals

### **TEACHING HOSPITAL**



# IBM/Watson Top 100 Everest Award





#### EL CAMINO HOSPITAL BOARD OF DIRECTORS BOARD MEETING MEMO

**To:** El Camino Hospital Board of Directors

From: Mary Rotunno, Legal Counsel

**Date:** May 12, 2021

**Subject:** Draft Revised Hospital Board Officers Nomination and Selection Procedures

#### **Recommendation(s):**

To approve the Draft Revised Hospital Board Officers Nomination and Selection Procedures.

#### **Summary:**

- 1. <u>Situation</u>: At the April 7, 2001 meeting, the Board approved a revision to the Board Officer Nominations and Selections Procedures indicating a simultaneous paper vote with validation by a neutral party who will announce the vote. Due to the pandemic, all meetings are virtual, which creates difficulty in executing a traditional "paper vote." The approved procedures also did not allow nominations to be taken from the floor for Vice-Chair and Secretary/Treasurer which has been the historical practice.
- 2. <u>Assessment:</u> The intent of a paper vote is to allow Board members to submit their vote to a neutral party without knowledge of other Board members' votes. An equivalent process can be executed electronically and the proposed revised procedures allow for electronic submission of Board member votes. Additionally, language was included to allow nominations from the floor for Hospital Vice-Chair and Secretary/Treasurer, in addition to Directors announcing their candidacy at the meeting.

#### **List of Attachments:**

1. Draft Revised Hospital Board Officers Nomination and Selection Procedures



2500 Grant Road Mountain View, CA 94040-4378 Phone: 650-940-7000 www.elcaminohospital.org

#### HOSPITAL BOARD OFFICERS NOMINATION AND SELECTION PROCEDURES FOR FY21

Draft Revised 04-/07/2021/05/12/2021

Any current director of the El Camino Hospital Board is eligible to serve as a Hospital Board Officer. The new Hospital Board Officer terms begin July 1, 2021. El Camino Hospital Board Officer elections shall be held in May of odd numbered years. Following the election, it shall be the role of the Board Chair-Elect to work with the Hospital CEO in May and June to develop a slate of Board Advisory Committee Chairs and members for the following fiscal year and to present the slate to the Board for approval in June.

#### **Hospital Board Chair:**

- Interested Directors will declare their interest to the CEO or designee by close of business April 22, 2021. The CEO or designee will notify the Board of all declarations of interest by close of business April 23, 2021. Any other interested Directors will then declare their interest to the CEO or designee by close of business on April 26, 2021. The CEO or designee will notify the Board of any additional declarations of interest by close of business April 27, 2021. Interested Directors will prepare a one-page Position Statement that summarizes the candidate's interest and relevant experience as it relates to the attached Hospital Board Chair competencies, no later than close of business April 29, 2021.
- 2. Position Statements will be distributed to Board members along with other routine Hospital Board materials one week in advance of the May 12, 2021 meeting.
- 3. Position Statements will be made available to the public and posted on the El Camino Hospital website when the Hospital Board materials are issued to the Board.
- 4. Standard questions for Hospital Board Chair:
  - a. What do you see as the ECH strategic priorities over the coming two years?
  - b. Name three defining roles of an effective Board Chair.
  - c. How would you judge the success of your leadership and the Board at the end of your term?
- 5. At the May 12, 2021 meeting, Interested Directors will present the information below, in public session, in the sequence outlined. Approximately 25 minutes will be allocated to each Interested Director: five (5) minutes for the Position Statement, ten (10) minutes for responses to standard questions, and (10) ten minutes to respond to general questions from the board and public:
  - a. Each interested director will read his or her Position Statement
  - b. Each interested director will provide responses to the standard questions. (Directors will present one question at a time in random order.)
  - c. The Public will be invited to ask Interested Directors any questions related to the candidate's interest in the position, and relevant experience as it relates to the Hospital Board Chair competencies
  - d. The Board will be invited to ask Interested Directors any additional questions related to an Interested Director's candidacy.

- 6. Upon review and discussion of the candidates, the Board will vote in public session. The current Chair will facilitate the discussion and voting process.
- 7. The Hospital Board Chair will be elected by the Board in accordance with the following procedure at a meeting where a quorum is present.

#### a. Preliminary Balloting

- i. Each Board member shall vote for a candidate via <u>electronic submission simultaneous</u> <u>paper ballot.roll calsimultaneously to a neutral party who will announce the vote cast</u> by each Director.<del>!.</del>
- ii. In the event a majority is not achieved, the vote will be announced for each candidate and the candidate receiving the lowest number of votes will be dropped from the next ballot.
- iii. This procedure will continue until one candidate receives a majority of the votes cast.
- iv. In the event a tie vote occurs (e.g., 3-3 or 4-2-2), Interested Directors may be asked additional questions by Hospital Board members and the balloting procedure will continue until a majority is achieved by one candidate.

#### b. Selection of a Board Chair

- i. Following the preliminary balloting, the Board shall consider a motion to elect the candidate who has received the majority of the votes in his/her favor.
- ii. If a motion pursuant to Section 7(b)(i) is not adopted by a majority of the Board members present at the meeting when a quorum is present, the Board shall continue to consider motions until a Board Chair is elected.

#### **Hospital Vice-Chair:**

- 1. At the May 12, 2021 Hospital Board meeting, Interested Directors will announce their candidacy and/or nominations taken from the floor following the successful election of the Hospital Board Chair.
- 2. Interested Directors will be asked questions, which relate to the candidate's experience, by other Hospital Board members in public session.
- 3. Voting will follow the same procedure as described in the Hospital Board Chair selection and appointment process above.
- 4. The Vice Chair is the presumptive Chair at the end of the current Chair's term.

#### **Hospital Secretary/Treasurer:**

- 1. At the May 12, 2021 Hospital Board meeting, Interested Directors will announce their candidacy and/or nominations taken from the floor following the successful election of the Hospital Board Chair and the Hospital Vice-Chair.
- 2. Interested Directors will be asked questions, which relate to the candidate's experience, by other Hospital Board members in public session.
- 3. Voting will follow the same procedure as described in the Hospital Board Chair selection and appointment process above.



#### **EL CAMINO HOSPITAL BOARD MEETING COVER MEMO**

To: El Camino Hospital Board of Directors From: Mary Rotunno, General Counsel

May 12, 2021 Date:

**Board Officer Election Subject:** 

#### **Recommendation(s):**

| 1.   | Preliminary round of voting for the Board C | Chair by electronic submission simultaneously to a |
|------|---|--|
|      | neutral party who will announce the vote ca | st by each Director.                               |
| 2.   | Motion to select                            | as ECH Board Chair for a one year term of          |
|      | service effective July 1, 2021.             |  |
| 3.   | Motion to select                            | as ECH Board Vice-Chair for a two year term of     |
|      | service effective July 1, 2021.             |  |
| 4.   | Motion to select                            | as ECH Board Secretary/Treasurer for a two year    |
|      | term of service effective July 1, 2021.     | ,  |
| Sumr | nary:                                       |  |

- 1. Situation: Board Officers serve two year terms and the current Board Officers terms expire on June 30, 2021. At the April 7, 2021 meeting, the Board approved Resolution 2021-04 temporarily suspending the two term limit for the Board Chair to allow re-election of the current Board Chair for a one year term.
- 2. Authority: Board Officer Nomination and Selection Procedures provide the procedure to be followed.
- 3. Background: Current Board Chair Lanhee Chen is the only Director that has declared interest in the Board Chair position.
- 4. Assessment: N/A
- 5. Other Reviews: N/A
- 6. Outcomes: N/A

#### **List of Attachments:**

- 1. Board Officer Nomination and Selection Procedures with proposed revisions
- 2. Director Lanhee Chen's Position Statement

Suggested Board Discussion Questions: None.



2500 Grant Road Mountain View, CA 94040-4378 Phone: 650-940-7000 www.elcaminohospital.org

#### HOSPITAL BOARD OFFICERS NOMINATION AND SELECTION PROCEDURES FOR FY21

Draft Revised 04-/07/2021/05/12/2021

Any current director of the El Camino Hospital Board is eligible to serve as a Hospital Board Officer. The new Hospital Board Officer terms begin July 1, 2021. El Camino Hospital Board Officer elections shall be held in May of odd numbered years. Following the election, it shall be the role of the Board Chair-Elect to work with the Hospital CEO in May and June to develop a slate of Board Advisory Committee Chairs and members for the following fiscal year and to present the slate to the Board for approval in June.

#### **Hospital Board Chair:**

- Interested Directors will declare their interest to the CEO or designee by close of business April 22, 2021. The CEO or designee will notify the Board of all declarations of interest by close of business April 23, 2021. Any other interested Directors will then declare their interest to the CEO or designee by close of business on April 26, 2021. The CEO or designee will notify the Board of any additional declarations of interest by close of business April 27, 2021. Interested Directors will prepare a one-page Position Statement that summarizes the candidate's interest and relevant experience as it relates to the attached Hospital Board Chair competencies, no later than close of business April 29, 2021.
- 2. Position Statements will be distributed to Board members along with other routine Hospital Board materials one week in advance of the May 12, 2021 meeting.
- 3. Position Statements will be made available to the public and posted on the El Camino Hospital website when the Hospital Board materials are issued to the Board.
- 4. Standard questions for Hospital Board Chair:
  - a. What do you see as the ECH strategic priorities over the coming two years?
  - b. Name three defining roles of an effective Board Chair.
  - c. How would you judge the success of your leadership and the Board at the end of your term?
- 5. At the May 12, 2021 meeting, Interested Directors will present the information below, in public session, in the sequence outlined. Approximately 25 minutes will be allocated to each Interested Director: five (5) minutes for the Position Statement, ten (10) minutes for responses to standard questions, and (10) ten minutes to respond to general questions from the board and public:
  - a. Each interested director will read his or her Position Statement
  - b. Each interested director will provide responses to the standard questions. (Directors will present one question at a time in random order.)
  - c. The Public will be invited to ask Interested Directors any questions related to the candidate's interest in the position, and relevant experience as it relates to the Hospital Board Chair competencies
  - d. The Board will be invited to ask Interested Directors any additional questions related to an Interested Director's candidacy.

- 6. Upon review and discussion of the candidates, the Board will vote in public session. The current Chair will facilitate the discussion and voting process.
- 7. The Hospital Board Chair will be elected by the Board in accordance with the following procedure at a meeting where a quorum is present.

#### a. Preliminary Balloting

- i. Each Board member shall vote for a candidate via <u>electronic submission simultaneous</u> <u>paper ballot.roll calsimultaneously to a neutral party who will announce the vote cast</u> by each Director.<del>!.</del>
- ii. In the event a majority is not achieved, the vote will be announced for each candidate and the candidate receiving the lowest number of votes will be dropped from the next ballot.
- iii. This procedure will continue until one candidate receives a majority of the votes cast.
- iv. In the event a tie vote occurs (e.g., 3-3 or 4-2-2), Interested Directors may be asked additional questions by Hospital Board members and the balloting procedure will continue until a majority is achieved by one candidate.

#### b. Selection of a Board Chair

- i. Following the preliminary balloting, the Board shall consider a motion to elect the candidate who has received the majority of the votes in his/her favor.
- ii. If a motion pursuant to Section 7(b)(i) is not adopted by a majority of the Board members present at the meeting when a quorum is present, the Board shall continue to consider motions until a Board Chair is elected.

#### **Hospital Vice-Chair:**

- 1. At the May 12, 2021 Hospital Board meeting, Interested Directors will announce their candidacy and/or nominations taken from the floor following the successful election of the Hospital Board Chair.
- 2. Interested Directors will be asked questions, which relate to the candidate's experience, by other Hospital Board members in public session.
- 3. Voting will follow the same procedure as described in the Hospital Board Chair selection and appointment process above.
- 4. The Vice Chair is the presumptive Chair at the end of the current Chair's term.

#### **Hospital Secretary/Treasurer:**

- 1. At the May 12, 2021 Hospital Board meeting, Interested Directors will announce their candidacy and/or nominations taken from the floor following the successful election of the Hospital Board Chair and the Hospital Vice-Chair.
- 2. Interested Directors will be asked questions, which relate to the candidate's experience, by other Hospital Board members in public session.
- 3. Voting will follow the same procedure as described in the Hospital Board Chair selection and appointment process above.



#### EL CAMINO HOSPITAL BOARD OF DIRECTORS

**To:** El Camino Hospital Board of Directors **From:** Lanhee J. Chen, J.D., Ph.D., Board Chair

**Date:** May 12, 2021

**Subject:** Hospital Board Chair Position Statement

It has been a great honor and privilege to serve as the Chair of the El Camino Hospital Board of Directors over the past several years. Together, we have embarked on a journey toward creating a high-performing, high-quality health care system while also formulating a new strategic vision for the years to come. All the while, we have remained an institution that remains fundamentally committed to the communities we serve.

As we complete our strategic planning process and begin to execute upon the priorities that emerge from it, I am asking for your support to serve for an additional year as Board Chair. This is a critical time for El Camino Health and I believe it is essential for our system to continue to build upon the very good progress we have made over the last several years. I believe that now is a time for continuity in leadership.

That being said, it is also important for us to institute a succession planning process for the leadership of our Board in the years ahead. I intend to work closely with whoever is elected as Vice Chair of the Board of Directors to ensure an orderly and successful transition at the end of my service as Chair.

The values that are important for dynamic and effective leadership — vision, consensus-building, mutual respect, and effective communication — are the ones that I believe have guided my time as Chair, and that will continue to inform my work if you give me the honor of continuing in this role for the next year.



### **Summary of Financial Operations**

Fiscal Year 2021 – Period 9 7/1/2020 to 03/31/2021

## **Executive Summary - Overall Commentary for Period 9**

- Strong operating / financial results for Period 9 were attributed to the following:
  - Significant decrease of Covid-19 patients
  - Rebound in procedural volumes due to pent up demand from January and February
  - Focus on management of OT / premium pay, ALOS and variable expenses
  - Stable payor mix
- Total gross charges, a surrogate for volume, were favorable to budget by \$87.3M / 29.1% and \$105.9M / 37.6% higher than the same period last year
- Net patient revenue was favorable to budget by \$17.3M / 21.6% and \$24.1M / 32.9% higher than the same period last year
- Operating expenses were \$9.3M /11.2% unfavorable to budget, which is primarily attributed to higher than expected volume versus budget and significant number of procedural cases performed in March
- Operating margin was favorable to budget by \$7.1M / 619.3% and \$17.9M / 185.5% higher than the same period last year
- Operating EBIDA was favorable to budget by \$6.9M / 90.9% and \$18.4M / 478.9% higher than the same period last year



### Operational / Financial Results: Period 9 – March 2021 (as of 3/31/2021)

#### **PERIOD 9 - RESULTS**

| (\$ thousands)    |                              | Current Year | Budget  | Variance to<br>Budget | Performance<br>to Budget | Prior Year | Variance to<br>Prior Year | Variance to<br>Prior Year |
|-------------------|------------------------------|--------------|---------|-----------------------|--------------------------|------------|---------------------------|---------------------------|
|                   | ADC                          | 231          | 217     | 15                    | 6.7%                     | 218        | 13                        | 6.1%                      |
|                   | Total Discharges             | 1,939        | 1,867   | 72                    | 3.9%                     | 1,810      | 129                       | 7.1%                      |
| Activity / Volume | Adjusted Discharges          | 3,244        | 2,802   | 442                   | 15.8%                    | 2,584      | 660                       | 25.5%                     |
| Activity / Volume | Emergency Room Visits        | 4,271        | 4,077   | 194                   | 4.8%                     | 4,624      | (353)                     | -7.6%                     |
|                   | OP Procedural Cases          | 15,665       | 8,139   | 7,526                 | 92.5%                    | 7,318      | 8,347                     | 114.1%                    |
|                   | Gross Charges (\$)           | 387,620      | 300,318 | 87,302                | 29.1%                    | 281,723    | 105,897                   | 37.6%                     |
| Operations        | Total FTEs                   | 2,875        | 2,855   | 20                    | 0.7%                     | 2,827      | 48                        | 1.7%                      |
|                   | Productive Hrs. / APD        | 31.8         | 33.4    | (1.6)                 | -4.7%                    | 38.1       | (6.3)                     | -16.5%                    |
|                   | Cost Per Adjusted Discharge  | 16,509       | 17,901  | (1,392)               | -7.8%                    | 20,136     | (3,627)                   | -18.0%                    |
|                   | Net Days in A/R              | 50.9         | 49.0    | 1.9                   | 3.8%                     | 49.1       | 1.7                       | 3.5%                      |
|                   | Net Patient Revenue (\$)     | 97,171       | 79,886  | 17,285                | 21.6%                    | 73,105     | 24,066                    | 32.9%                     |
|                   | Total Operating Revenue (\$) | 100,708      | 84,265  | 16,444                | 19.5%                    | 77,345     | 23,364                    | 30.2%                     |
|                   | Operating Margin (\$)        | 8,258        | 1,148   | 7,110                 | 619.3%                   | (9,658)    | 17,917                    | 185.5%                    |
| Financial         | Operating EBIDA (\$)         | 14,588       | 7,641   | 6,947                 | 90.9%                    | (3,850)    | 18,438                    | 478.9%                    |
| Performance       | Net Margin (\$)              | 27,223       | 4,482   | 22,742                | 507.4%                   | (81,470)   | 108,694                   | 133.4%                    |
|                   | Operating Margin (%)         | 8.2%         | 1.4%    | 6.8%                  | 501.9%                   | -12.5%     | 20.7%                     | 165.7%                    |
|                   | Operating EBIDA Margin (%)   | 14.5%        | 9.1%    | 5.4%                  | 59.7%                    | -5.0%      | 19.5%                     | 391.0%                    |
|                   | DCOH (days)                  | 566          | 435     | 130                   | 29.9%                    | 432        | 134                       | 31.0%                     |

| Moody's | Medians | Performance        |
|---------|---------|--------------------|
| 'A1'    | 'Aa3'   | to 'A1'<br>Medians |
|         |         |                    |
|         |         |                    |
|         |         |                    |
|         |         |                    |
|         |         |                    |
|         |         |                    |
|         |         |                    |
|         |         |                    |
|         |         |                    |
| 47.7    | 47.1    |                    |
| 106,723 | 257,000 |                    |
| 116,864 | 314,648 |                    |
| 3,948   | 10,135  |                    |
| 11,301  | 27,969  |                    |
| 8,219   | 18,726  |                    |
| 2.9%    | 3.6%    |                    |
| 9.7%    | 8.9%    |                    |
| 254     | 264     |                    |

Moody's Medians: Not-for-profit and public healthcare annual report; September 9, 2020. Dollar amounts have been adjusted to reflect monthly averages.



### Operational / Financial Results: YTD FY2021 (as of 3/31/2021)

#### YTD FY2021 - RESULTS

| (\$ thousands)    |                              | Current Year | Budget    | Variance to<br>Budget | Performance<br>to Budget | Prior Year | Variance to<br>Prior Year | Variance to<br>Prior Year |
|-------------------|------------------------------|--------------|-----------|-----------------------|--------------------------|------------|---------------------------|---------------------------|
|                   | ADC                          | 241          | 205       | 36                    | 17.8%                    | 237        | 4                         | 1.6%                      |
|                   | Total Discharges             | 16,930       | 15,713    | 1,217                 | 7.7%                     | 18,157     | (1,227)                   | -6.8%                     |
| Activity / Volume | Adjusted Discharges          | 26,258       | 23,508    | 2,750                 | 11.7%                    | 28,185     | (1,927)                   | -6.8%                     |
| Activity / Volume | Emergency Room Visits        | 36,915       | 32,245    | 4,670                 | 14.5%                    | 46,709     | (9,794)                   | -21.0%                    |
|                   | OP Procedural Cases          | 119,491      | 70,228    | 49,263                | 70.1%                    | 84,722     | 34,769                    | 41.0%                     |
|                   | Gross Charges (\$)           | 3,143,811    | 2,498,291 | 645,520               | 25.8%                    | 2,885,575  | 258,236                   | 8.9%                      |
|                   | Total FTEs                   | 2,818        | 2,841     | (23)                  | -0.8%                    | 2,804      | 14                        | 0.5%                      |
| On a martine mar  | Productive Hrs. / APD        | 31.4         | 33.4      | (2.0)                 | -5.9%                    | 31.5       | (0.0)                     | -0.2%                     |
| Operations        | Cost Per Adjusted Discharge  | 17,198       | 18,458    | (1,260)               | -6.8%                    | 16,213     | 985                       | 6.1%                      |
|                   | Net Days in A/R              | 50.9         | 49.0      | 1.9                   | 3.8%                     | 49.1       | 1.7                       | 3.5%                      |
|                   | Net Patient Revenue (\$)     | 805,228      | 650,689   | 154,539               | 23.8%                    | 757,093    | 48,135                    | 6.4%                      |
|                   | Total Operating Revenue (\$) | 839,876      | 692,263   | 147,612               | 21.3%                    | 798,176    | 41,700                    | 5.2%                      |
|                   | Operating Margin (\$)        | 47,365       | (30,980)  | 78,345                | 252.9%                   | 51,782     | (4,417)                   | -8.5%                     |
| Financial         | Operating EBIDA (\$)         | 110,488      | 29,253    | 81,235                | 277.7%                   | 97,744     | 12,744                    | 13.0%                     |
| Performance       | Net Margin (\$)              | 222,346      | (5,476)   | 227,821               | 4160.6%                  | 4,430      | 217,915                   | 4918.6%                   |
|                   | Operating Margin (%)         | 5.6%         | -4.5%     | 10.1%                 | 226.0%                   | 6.5%       | -0.8%                     | -13.1%                    |
|                   | Operating EBIDA Margin (%)   | 13.2%        | 4.2%      | 8.9%                  | 211.3%                   | 12.2%      | 0.9%                      | 7.4%                      |
|                   | DCOH (days)                  | 566          | 435       | 130                   | 29.9%                    | 432        | 134                       | 31.0%                     |

| Moody's   | Medians   | Performance        |
|-----------|-----------|--------------------|
| 'A1'      | 'Aa3'     | to 'A1'<br>Medians |
|           |           |                    |
|           |           |                    |
|           |           |                    |
|           |           |                    |
|           |           |                    |
|           |           |                    |
|           |           |                    |
|           |           |                    |
|           |           |                    |
| 47.7      | 47.1      |                    |
| 960,503   | 2,312,999 |                    |
| 1,051,776 | 2,831,833 |                    |
| 35,536    | 91,211    |                    |
| 101,705   | 251,718   |                    |
| 73,967    | 168,533   |                    |
| 2.9%      | 3.6%      |                    |
| 9.7%      | 8.9%      |                    |
| 254       | 264       |                    |

Moody's Medians: Not-for-profit and public healthcare annual report; September 9, 2020. Dollar amounts have been adjusted to reflect 9 month totals.



## Key Statistics: Period 9 and YTD (as of 03/31/2021)

| _                             | Mor    | ith to Da | te     | Variar   | nce (%)      | _   | Ye      | ar to Dat | e      | Varian   | ce (%)       |  |
|-------------------------------|--------|-----------|--------|----------|--------------|-----|---------|-----------|--------|----------|--------------|--|
| Key Statistics                | PY     | CY        | Budget | CY vs PY | CY vs Budget |     | PY      | CY        | Budget | CY vs PY | CY vs Budget |  |
| ADC                           | 218    | 231       | 217    | 6.1%     | 6.7%         |     | 237     | 241       | 205    | 1.6%     | 17.8%        |  |
| Utilization MV                | 59%    | 62%       | 57%    | 5.8%     | 8.0%         | 1   | 65%     | 63%       | 53%    | (2.6%)   | 18.0%        |  |
| Utilization LG                | 30%    | 27%       | 27%    | (8.8%)   | 0.5%         | 1   | 30%     | 31%       | 27%    | 4.4%     | 17.0%        |  |
| Utilization Combined          | 49%    | 51%       | 48%    | 3.5%     | 6.7%         | -   | 54%     | 53%       | 45%    | (0.9%)   | 17.7%        |  |
| Adjusted Discharges           | 2,584  | 3,244     | 2,802  | 25.5%    | 15.8%        | -   | 28,185  | 26,258    | 23,508 | (6.8%)   | 11.7%        |  |
| Total Discharges (Exc NB)     | 1,490  | 1,611     | 1,515  | 8.1%     | 6.4%         | 1   | 15,056  | 14,027    | 12,663 | (6.8%)   | 10.8%        |  |
| Total Discharges              | 1,810  | 1,939     | 1,867  | 7.1%     | 3.9%         |     | 18,157  | 16,930    | 15,713 | (6.8%)   | 7.7%         |  |
| Inpatient Activity            |        |           |        |          |              |     |         |           |        |          |              |  |
| MS Discharges                 | 1,015  | 1,104     | 952    | 8.8%     | 15.9%        | -   | 10,456  | 9,583     | 7,885  | (8.3%)   | 21.5%        |  |
| Deliveries _                  | 333    | 354       | 372    | 6.3%     | (4.9%)       |     | 3,278   | 3,116     | 3,222  | (4.9%)   | (3.3%)       |  |
| BHS                           | 100    | 120       | 146    | 20.0%    | (17.8%)      |     | 917     | 953       | 1,164  | 3.9%     | (18.1%)      |  |
| Rehab                         | 42     | 33        | 44     | (21.4%)  | (24.8%)      | 1   | 405     | 375       | 393    | (7.4%)   | (4.5%)       |  |
| <b>Outpatient Activity</b>    |        |           |        |          |              | ١,  |         |           |        |          | _            |  |
| <b>Total Outpatient Cases</b> | 10,324 | 18,738    | 11,241 | 81.5%    | 66.7%        |     | 120,732 | 146,673   | 94,523 | 21.5%    | 55.2%        |  |
| ED _                          | 3,006  | 3,073     | 3,102  | 2.2%     | (0.9%)       |     | 36,010  | 27,182    | 24,295 | (24.5%)  | 11.9%        |  |
| OP Surg                       | 342    | 614       | 351    | 79.5%    | 74.9%        |     | 4,340   | 4,626     | 3,031  | 6.6%     | 52.6%        |  |
| Endo                          | 150    | 252       | 163    | 68.0%    | 54.4%        | - 1 | 1,959   | 1,887     | 1,318  | (3.7%)   | 43.1%        |  |
| Interventional                | 149    | 194       | 133    | 30.2%    | 45.5%        | - 1 | 1,590   | 1,536     | 985    | (3.4%)   | 55.9%        |  |
| All Other                     | 6,677  | 14,605    | 7,491  | 118.7%   | 95.0%        | -   | 76,833  | 111,442   | 64,894 | 45.0%    | 71.7%        |  |
| Hospital Payor Mix            |        |           |        |          |              | -   |         |           |        |          |              |  |
| Medicare                      | 46.0%  | 48.7%     | 48.7%  | 5.8%     | (0.1%)       | -   | 48.9%   | 48.3%     | 48.5%  | (1.1%)   | (0.3%)       |  |
| Medi-Cal                      | 8.0%   | 8.0%      | 7.5%   | -0.7%    | 5.8%         |     | 7.5%    | 8.2%      | 7.5%   | 10.2%    | 9.3%         |  |
| Commercial                    | 43.4%  | 40.4%     | 41.4%  | -6.9%    | (2.6%)       |     | 41.3%   | 41.1%     | 41.6%  | -0.4%    | (1.2%)       |  |
| Other                         | 2.6%   | 3.0%      | 2.3%   | 15.4%    | 21.1%        |     | 2.3%    | 2.3%      | 2.4%   | (1.8%)   | (5.4%)       |  |



## **Income Statement: Current Fiscal Year Monthly Trend (\$000s)**

|                              | Period 1<br>Jul-20 | Period 2<br>Aug-20 | Period 3<br>Sep-20 | Period 4<br>Oct-20 | Period 5<br>Nov-20 | Period 6<br>Dec-20 | Period 7<br>Jan-21 | Period 8<br>Feb-21 | Period 9<br>Mar-21 | Period 10<br>Apr-21 | Period 11<br>May-21 | Period 12<br>Jun-21 | YTD FY2021  | YTD Monthly<br>Average |
|------------------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|---------------------|---------------------|---------------------|-------------|------------------------|
| Operating Revenues:          |                    |                    |                    |                    |                    |                    |                    |                    |                    |                     |                     |                     |             |                        |
| Gross Revenue                | 333,228            | 339,121            | 357,838            | 366,453            | 341,648            | 367,494            | 335,788            | 314,620            | 387,620            | -                   | -                   | -                   | 3,143,811   | 349,312                |
| Deductions from Revenue      | (247,360)          | (253,449)          | (267,829)          | (275,898)          | (253,051)          | (275,206)          | (245,993)          | (229,347)          | (290,449)          | -                   | -                   |                     | (2,338,582) | (259,842)              |
| Net Patient Revenue          | 85,868             | 85,672             | 90,009             | 90,554             | 88,597             | 92,289             | 89,795             | 85,273             | 97,171             | -                   | -                   | -                   | 805,228     | 89,470                 |
| Other Operating Revenue      | 4,667              | 4,331              | 3,996              | 4,024              | 3,234              | 3,079              | 4,427              | 3,352              | 3,537              | -                   | -                   | -                   | 34,647      | 3,850                  |
| Total Operating Revenue      | 90,535             | 90,003             | 94,005             | 94,578             | 91,831             | 95,368             | 94,222             | 88,625             | 100,708            | -                   | -                   | -                   | 839,876     | 93,320                 |
| Operating Expenses:          |                    |                    |                    |                    |                    |                    |                    |                    |                    |                     |                     |                     |             |                        |
| Salaries, Wages and Benefits | 46,431             | 47,739             | 48,136             | 49,061             | 47,222             | 48,774             | 53,636             | 48,592             | 52,025             | -                   | -                   | -                   | 441,616     | 49,068                 |
| Supplies                     | 12,820             | 16,893             | 12,798             | 13,496             | 13,641             | 14,519             | 13,888             | 13,587             | 15,421             | -                   | -                   | -                   | 127,062     | 14,118                 |
| Fees & Purchased Services    | 12,918             | 14,366             | 14,949             | 12,982             | 14,264             | 14,035             | 15,825             | 14,770             | 15,139             | -                   | -                   | -                   | 129,248     | 14,361                 |
| Other Operating Expenses     | 3,583              | 3,596              | 4,498              | 3,721              | 3,512              | 4,100              | 3,819              | 1,097              | 3,536              | -                   | -                   | -                   | 31,462      | 3,496                  |
| Interest                     | 1,428              | 1,431              | 1,428              | 1,429              | 1,428              | 1,428              | 1,428              | 1,392              | 1,399              | -                   | -                   | -                   | 12,791      | 1,421                  |
| Depreciation                 | 5,231              | 5,328              | 5,795              | 5,798              | 6,068              | 5,591              | 5,689              | 5,903              | 4,931              | -                   | -                   | -                   | 50,332      | 5,592                  |
| Total Operating Expenses     | 82,411             | 89,352             | 87,604             | 86,487             | 86,136             | 88,446             | 94,284             | 85,341             | 92,450             | -                   | -                   | -                   | 792,511     | 88,057                 |
| Operating Margin             | 8,124              | 651                | 6,401              | 8,091              | 5,695              | 6,922              | (62)               | 3,285              | 8,258              | -                   | -                   | -                   | 47,365      | 5,263                  |
| Non-Operating Income         | 27,718             | 28,642             | (9,557)            | (27,499)           | 64,968             | 57,357             | 39                 | 14,349             | 18,965             | _                   | -                   | -                   | 174,981     | 19,442                 |
| Net Margin                   | 35,842             | 29,293             | (3,156)            | (19,408)           | 70,663             | 64,279             | (23)               | 17,633             | 27,223             | -                   | -                   | -                   | 222,346     | 24,705                 |
| Operating EBIDA              | 14,783             | 7,410              | 13,624             | 15,318             | 13,192             | 13,940             | 7,055              | 10,580             | 14,588             | -                   | -                   | -                   | 110,488     | 12,276                 |
| Operating Margin (%)         | 9.0%               | 0.7%               | 6.8%               | 8.6%               | 6.2%               | 7.3%               | -0.1%              | 3.7%               | 8.2%               |                     |                     |                     | 5.6%        |                        |
| Operating EBIDA Margin (%)   | 16.3%              | 8.2%               | 14.5%              | 16.2%              | 14.4%              | 14.6%              | 7.5%               | 11.9%              | 14.5%              |                     |                     |                     | 13.2%       |                        |



### Financial Overview: Period 9 - March 2021

Period ending 3/31/2021

### **Financial Performance**

- March operating income was \$8.3M compared to a budget of \$1.1M, resulting in a favorable variance of \$7.1M. The primary drivers are volume which rebounded from the third wave of the pandemic, pent up demand of surgical cases, stable payer mix and management of variable expenses
- March volumes and revenues continue to be stronger than budget as demonstrated by:
  - Adjusted discharges were favorable to budget by 442 cases / 15.8% and 660 cases / 25.6% above the same period last year
  - Favorable variance of gross charges of \$87.4M was split as follows:
    - Inpatient gross charges: Favorable to budget by \$30M / 19% variance primarily driven by surgery, cath. Lab, NICU and ancillary services
    - Outpatient gross charges: Favorable to budget by \$57M / 43% variance primarily driven by surgery, cath. lab, emergency room, and ancillary services
  - Operating Expenses were unfavorable to budget by \$9.3M / 11.2%, primarily due to patient activity, increased use / cost of PPE associated with Covid-19 and other Covid-19 associated expenses
    - SWB were unfavorable by \$5.4M / 12%
    - Supplies were unfavorable by \$2.9M / 36%
    - All other discretionary non-volume driven expenses were favorable to budget by \$1M
    - Additional expenses attributed to Covid-19 were \$1.6M in March and \$14.2M YTD
- Non Operating Income includes:
  - Favorable variance of \$15.6M primarily due to unrealized gains on investments



### Financial Overview: Period 9 – March 2021 (cont.)

Period ending 3/31/2021

### **Financial Performance**

### **Hospital Operations:**

- Adjusted Discharges (AD): Favorable to budget by 442 ADs / 16% and above prior year by 660 ADs / 26%:
  - Mountain View: Favorable to budget by 226 ADs / 10% and above prior year by 394 ADs/ 19%
  - Los Gatos: Favorable to budget by 216 ADs / 43% and above prior year by 266 ADs / 57%
- Operating Expense Per <u>CMI Adjusted Discharge</u>: \$16,508 which is 7.8% favorable to budget Note: Excludes depreciation and interest

### El Camino Health Medical Network (ECHMN) Operations:

- February's total visits of 26,454 was 16% above prior month and 25.2% favorable to budget and included 7,972 COVID vaccination visits
- Net Income was unfavorable to budget by \$760K in February, but was \$661K favorable to February of 2020
- YTD February ECHMN Net Income is unfavorable to budget by \$800K / 3.4%, but remains favorable to prior year by \$2.1M / 8.1%



### Financial Overview: YTD FY2021 (as of 3/31/2021)

### **Consolidated Financial Performance**

- YTD FY2021 net operating margin of \$47.4M compared to the budget of -\$31.0M
- Year-over-year operating margin is \$4.4M lower than the same period last year, which is primarily
  due to an increase in depreciation and interest expense of \$17M associated with recently completed
  capital projects at the Mountain View campus
- Strong volume recovery from the first wave of Covid-19, continues to be the primary driver of favorable performance to budget
  - Adjusted discharges are 2,736 /12% favorable to budget and 1,913 / 6.8% lower than the same period last year
- Operating expenses are \$69.3M / 9.6% unfavorable to budget
  - Unfavorability driven higher than budgeted volumes and expenses associated with Covid-19 pandemic
  - Operating expense per CMI adjusted discharge of \$17,292 is 10% favorable to budget which demonstrates consistent management of variable expenses

Note: Excludes depreciation and interest expense






## **APPENDIX**



### YTD FY2021 Financial KPIs – Monthly Trends





## **Consolidated Statement of Operations (\$000s)**

Period 9 ending 03/31/2021

|   | Period 9  | Period 9  | Period 9           | Variance    |         |                                 | YTD         | YTD         | YTD                | Variance    |           |
|---|-----------|-----------|--------------------|-------------|---------|---------------------------------|-------------|-------------|--------------------|-------------|-----------|
|   | FY 2020   | FY 2021   | <b>Budget 2021</b> | Fav (Unfav) | Var%    | \$000s                          | FY 2020     | FY 2021     | <b>Budget 2021</b> | Fav (Unfav) | Var%      |
|   |           |           |                    |             |         | OPERATING REVENUE               |             |             |                    |             | _         |
|   | 281,723   | 387,620   | 300,318            | 87,302      | 29.1%   | <b>Gross Revenue</b>            | 2,885,575   | 3,143,811   | 2,498,291          | 645,520     | 25.8%     |
|   | (208,618) | (290,449) | (220,432)          | (70,018)    | (31.8%) | Deductions                      | (2,128,482) | (2,338,582) | (1,847,602)        | (490,980)   | (26.6%)   |
|   | 73,105    | 97,171    | 79,886             | 17,285      | 21.6%   | <b>Net Patient Revenue</b>      | 757,093     | 805,228     | 650,689            | 154,539     | 23.8%     |
|   | 4,240     | 3,537     | 4,379              | (841)       | (19.2%) | Other Operating Revenue         | 41,082      | 34,647      | 41,574             | (6,927)     | (16.7%)   |
|   | 77,345    | 100,708   | 84,265             | 16,444      | 19.5%   | <b>Total Operating Revenues</b> | 798,176     | 839,876     | 692,263            | 147,612     | 21.3%     |
|   |           |           |                    |             |         | OPERATING EXPENSE               |             |             |                    |             |           |
|   | 48,720    | 52,025    | 46,617             | (5,408)     | (11.6%) | Salaries & Wages                | 418,542     | 441,616     | 400,287            | (41,329)    | (10.3%)   |
|   | 14,730    | 15,421    | 11,766             | (3,655)     | (31.1%) | Supplies                        | 120,970     | 127,062     | 100,015            | (27,047)    | (27.0%)   |
|   | 13,704    | 15,139    | 14,570             | (569)       | (3.9%)  | Fees & Purchased Services       | 126,788     | 129,248     | 129,586            | 338         | 0.3%      |
|   | 4,042     | 3,536     | 3,671              | 135         | 3.7%    | Other Operating Expense         | 34,132      | 31,462      | 33,122             | 1,660       | 5.0%      |
|   | 992       | 1,399     | 916                | (484)       | (52.8%) | Interest                        | 5,218       | 12,791      | 8,311              | (4,480)     | (53.9%)   |
|   | 4,817     | 4,931     | 5,577              | 647         | 11.6%   | Depreciation                    | 40,744      | 50,332      | 51,922             | 1,590       | 3.1%      |
|   | 87,003    | 92,450    | 83,117             | (9,333)     | (11.2%) | <b>Total Operating Expenses</b> | 746,394     | 792,511     | 723,243            | (69,268)    | (9.6%)    |
|   | (9,658)   | 8,258     | 1,148              | 7,110       | 619.3%  | <b>Net Operating Margin</b>     | 51,782      | 47,365      | (30,980)           | 78,345      | (252.9%)  |
|   |           |           |                    |             |         |                                 |             |             |                    |             |           |
|   | (71,812)  | 18,965    | 3,334              | 15,632      | 468.9%  | Non Operating Income            | (47,351)    | 174,981     | 25,504             | 149,477     | 586.1%    |
| _ | (81,470)  | 27,223    | 4,482              | 22,742      | 507.4%  | Net Margin                      | 4,430       | 222,346     | (5,476)            | 227,821     | (4160.6%) |
|   | (3,850)   | 14,588    | 7,641              | 6,947       | 90.9%   | Operating EBIDA                 | 97,744      | 110,488     | 29,253             | 81,235      | 277.7%    |
|   |           |           |                    |             |         |                                 |             |             |                    |             |           |
|   | -5.0%     | 14.5%     | 9.1%               | 5.4%        |         | Operating EBIDA Margin          | 12.2%       | 13.2%       | 4.2%               | 8.9%        |           |
|   | -12.5%    | 8.2%      | 1.4%               | 6.8%        |         | Operating Margin                | 6.5%        | 5.6%        | -4.5%              | 10.1%       |           |
|   | -105.3%   | 27.0%     | 5.3%               | 21.7%       |         | Net Margin                      | 0.6%        | 26.5%       | -0.8%              | 27.3%       |           |



## Consolidated Balance Sheet (as of 03/31/2021)

PROPERTY AND EQUIPMENT

**Construction in Progress** 

Less: Accumulated Depreciation

Property, Plant & Equipment - Net

Fixed Assets at Cost

**DEFERRED OUTFLOWS** 

RESTRICTED ASSETS

(\$000s)

| ASSETS                                  |                |               |
|---|----------------|---------------|
|   |                | Audited       |
| CURRENT ASSETS                          | March 31, 2021 | June 30, 2020 |
| Cash                                    | 197,255        | 228,464       |
| Short Term Investments                  | 275,289        | 221,604       |
| Patient Accounts Receivable, net        | 152,190        | 128,564       |
| Other Accounts and Notes Receivable     | (817)          | 13,811        |
| Intercompany Receivables                | 35,428         | 72,592        |
| Inventories and Prepaids                | 25,310         | 101,267       |
| Total Current Assets                    | 684,655        | 766,303       |
|   |                |               |
| BOARD DESIGNATED ASSETS                 | 10.000         | 45.264        |
| Foundation Board Designated             | 18,989         | 15,364        |
| Plant & Equipment Fund                  | 230,810        | 166,859       |
| Women's Hospital Expansion              | 30,401         | 22,563        |
| Operational Reserve Fund                | 159,902        | 148,917       |
| Community Benefit Fund                  | 19,459         | 17,916        |
| Workers Compensation Reserve Fund       | 16,482         | 16,482        |
| Postretirement Health/Life Reserve Fund | 31,365         | 30,731        |
| PTO Liability Fund                      | 30,394         | 27,515        |
| Malpractice Reserve Fund                | 1,965          | 1,919         |
| Catastrophic Reserves Fund              | 23,802         | 17,667        |
| Total Board Designated Assets           | 563,568        | 465,933       |
| FUNDO UELO DY TRUCTES                   | 0.500          | 22.470        |
| FUNDS HELD BY TRUSTEE                   | 8,589          | 23,478        |
| LONG TERM INVESTMENTS                   | 470,027        | 372,175       |
| CHARITABLE GIFT ANNUITY INVESTMENTS     | 712            | 680           |
| INVESTMENTS IN AFFILIATES               | 33,443         | 29,065        |
|   |                |               |

1,769,269

(726,689)

102,389

21,275

29,191

87,665

3,044,093

1,144,969

1,342,012

(676,535)

489,848

21,416

28,547

3,231

2,866,153

1,155,326

| LIABILITIES | V VID ELIVID |  |
|-------------|--------------|--|
|             |              |  |

|  |                | Audited       |
|--|----------------|---------------|
| CURRENT LIABILITIES                            | March 31, 2021 | June 30, 2020 |
| Accounts Payable                               | 29,390         | 35,323        |
| Salaries and Related Liabilities               | 38,274         | 35,209        |
| Accrued PTO                                    | 32,251         | 28,124        |
| Worker's Comp Reserve                          | 2,300          | 2,300         |
| Third Party Settlements                        | 13,418         | 10,956        |
| Intercompany Payables                          | 35,494         | 70,292        |
| Malpractice Reserves                           | 1,560          | 1,560         |
| Bonds Payable - Current                        | 9,430          | 9,020         |
| Bond Interest Payable                          | 3,317          | 8,463         |
| Other Liabilities                              | 11,444         | 3,222         |
| Total Current Liabilities                      | 176,877        | 204,469       |
| LONG TERM LIABILITIES Post Retirement Benefits | 31,547         | 30,731        |
| Worker's Comp Reserve                          | 16,482         | 16,482        |
| Other L/T Obligation (Asbestos)                | 6,100          | 4,094         |
| Bond Payable                                   | 485,447        | 513,602       |
| Total Long Term Liabilities                    | 539,575        | 564,908       |
| DEFERRED REVENUE-UNRESTRICTED                  | 77,200         | 77,133        |
| DEFERRED INFLOW OF RESOURCES                   | 31,009         | 30,700        |
| FUND BALANCE/CAPITAL ACCOUNTS                  |                |               |
| Unrestricted                                   | 1,994,341      | 1,771,854     |
| Board Designated                               | 194,031        | 188,457       |
| Restricted                                     | 31,060         | 28,631        |
| Total Fund Bal & Capital Accts                 | 2,219,432      | 1,988,942     |
| TOTAL LIABILITIES AND FUND BALANCE             | 3,044,093      | 2,866,153     |



## **Investment Scorecard (as of 12/31/2020)**

| Key Performance Indicator                 | Status | El Camino  | Benchmark                   | El Camino    | Benchmark    | El Camino              | Benchmark              | FY21 Budget | Expectation Per<br>Asset Allocation |
|---|--------|------------|-----------------------------|--------------|--------------|------------------------|------------------------|-------------|-------------------------------------|
| Investment Performance                    |        | CY 4Q 2020 | / FY 2Q 2021                | Fiscal Year- | to-Date 2021 |                        | e Inception<br>alized) | FY 2021     | 2019                                |
| Surplus cash balance*                     |        | \$1,302.1  |                             |              |              |                        |                        | -           | -                                   |
| Surplus cash return                       |        | 8.5%       | 8.0%                        | 13.0%        | 12.2%        | 6.6%                   | 6.4%                   | 4.0%        | 5.6%                                |
| Cash balance plan balance (millions)      |        | \$336.2    |                             | -            |              |                        |                        |             | -                                   |
| Cash balance plan return                  |        | 11.2%      | 9.2%                        | 17.1%        | 14.3%        | 8.9%                   | 7.9%                   | 6.0%        | 6.0%                                |
| 403(b) plan balance (millions)**          |        | \$581.5    |                             |              |              |                        |                        |             |                                     |
| Risk vs. Return                           | 3-y    | ear ear    |                             |              |              | e Inception<br>alized) |                        | 2019        |                                     |
| Surplus cash Sharpe ratio                 |        | 0.69       | 0.67                        |              |              | 0.93                   | 0.93                   |             | 0.34                                |
| Net of fee return                         |        | 7.8%       | 7.3%                        | -            |              | 6.6%                   | 6.4%                   |             | 5.6%                                |
| Standard deviation                        |        | 9.0%       | 8.6%                        | -            |              | 6.3%                   | 6.1%                   |             | 8.7%                                |
| Cash balance Sharpe ratio                 |        | 0.73       | 0.64                        |              |              | 1.00                   | 0.96                   |             | 0.32                                |
| Net of fee return                         |        | 9.8%       | 8.0%                        |              |              | 8.9%                   | 7.9%                   |             | 6.0%                                |
| Standard deviation                        |        | 11.4%      | 10.3%                       |              |              | 8.1%                   | 7.4%                   |             | 10.3%                               |
| Asset Allocation                          |        | CY 4Q 2020 | / FY 2Q 2021                |              |              |                        |                        |             |                                     |
| Surplus cash absolute variances to target |        | 9.4%       | < 10% Green<br>< 20% Yellow |              |              |                        |                        | -           | -                                   |
| Cash balance absolute variances to target |        | 7.9%       | < 10% Green<br>< 20% Yellow | -            |              |                        |                        | -           |                                     |
| Manager Compliance                        |        | CY 4Q 2020 | / FY 2Q 2021                |              |              |                        |                        |             |                                     |
| Surplus cash manager flags                |        | 16         | < 24 Green<br>< 30 Yellow   |              |              |                        |                        |             | -                                   |
| Cash balance plan manager flags           |        | 19         | < 27 Green<br>< 34 Yellow   |              |              |                        |                        | -           | -                                   |

<sup>\*</sup>Excludes debt reserve funds (~\$12 mm), District assets (~\$34 mm), and balance sheet cash not in investable portfolio (\$214 mm). Includes Foundation (~\$39 mm) and Concern (~\$15 mm) assets.

\*\*As of September 30, 2020 as more recent data not yet available.









### Minutes of the Open Session of the El Camino Hospital Board of Directors Wednesday, April 7, 2021

Pursuant to State of California Executive Order N-29-20 dated March 18, 2020, El Camino Health did not provide a physical location for this meeting. Instead, the public was invited to join the open session meeting via teleconference.

**Board Members Present Board Members Absent Members Excused** Lanhee Chen, Chair\*\* None None Peter C. Fung, MD\*\* Julie Kliger\*\* \*\*via teleconference Julia E. Miller, Secretary/Treasurer\*\* Jack Po, MD, Ph.D.\*\* **Bob Rebitzer\*\*** George O. Ting, MD\*\* Carol A. Somersille, MD\*\* Don Watters\*\* John Zoglin, Vice-Chair\*\*

| Ag | genda Item  | Comments/Discussion   | Approvals/<br>Action |
|----|---|---|----------------------|
| 1. | The open session meeting of the Board of Directors of El Camino Hospital (the "Board") was called to order at 5:30pm by Chair Chen. A verbal roll call was taken. Director Rebitzer joined at 5:37pm during the Board recognition, and Director Watters joined at 5:57pm during the FY21 Period 8 Financials. All other Board members were present at roll call. All members participated via videoconference pursuant to Santa Clara County' shelter in place order. Chair Chen reviewed the logistics for the meeting. A quorum was present pursuant to State of California Executive Orders N-25-20 dated March 12, 2020, and N-29-20 dated March 18, 2020.  Chair Chen asked if any Board members may have a conflict of interest with any of the items on the agenda. No conflicts were noted.  COMMUNICATION  Dim Griffith, Chief Operating Officer, honored and acknowledged the COVID-19 vaccination program team for their service, support, and dedication to the effort to immunize the community. |   |                      |
| 2. | CONFLICTS OF INTEREST   |   |                      |
| 3. |   | None.   |                      |
| 4. | 03: BOARD   | COVID-19 vaccination program team for their service, support, and dedication to the effort to immunize the community.  Motion: To approve Resolution 2021-03 recognizing the El Camino Health vaccine program team.  Movant: Miller Second: Ting Ayes: Chen, Fung, Kliger, Miller, Po, Rebitzer, Somersille, Ting, Zoglin | Motion<br>approved   |
| 5. | QUALITY<br>COMMITTEE<br>REPORT  | Director Kliger, Quality Committee Chair, provided an overview of the discussion at the April 6, 2021, Quality Committee meeting:   |                      |

- Discussion ensued regarding indicators moving away from target, which resulted in members inquiring how to decipher what metrics are in control versus out of control. It was agreed that there needs to be further education on this topic, given that it can be challenging to determine which metrics require greater attention and oversight.
- The committee is strategizing on ideas to elevate the voice of the patients within the meetings and is an open topic for continued discussion.
- The committee reviewed and approved the FY22 strategic goals in principle; there was a divide between members regarding whether mortality should still be considered a strategic goal.

In closing, Director Kliger commended the leadership team and staff for their hard work to ensure a positive bonus on value-based purchasing and noted that El Camino Health received formal recognition for being outstanding in several nursing indicators.

### 6. FY21 PERIOD 8 FINANCIALS

Carlos Bohorquez, Chief Financial Officer, provided an overview of the FY21 Period 8 Financials. He noted that the third wave of COVID-19 case rises drove the financials for this period. He further highlighted the following:

- Given the increase in COVID-positive patients in January, there was a significant strain on operations to step up and address the community's needs first and foremost. This affected the ability to conduct elective surgery on the Mountain View campus, thus yielding unfavorable outcomes in revenue.
- The financial operating budget was prepared conservatively but is overall positive, and further mentioned that there had been a decrease in assets due to the opening of Taube and Sobrato Pavilions.

Mr. Bohorquez stated that despite the uncertainty and volatility in COVID volumes, ECH has successfully adjusted.

- Mr. Bohorquez explained that Q4 financials are currently being prepared and that COVID is being accounted for. However, since there is high hopes for the vaccine, a fourth wave has not yet been reflected in those financials.
- Mr. Bohorquez addressed the dip between the months of February and March, explaining that it is attributed to the overall volume in NICU (newborn intensive care unit). It tends to fluctuate, but nothing that could be identified as a spectacular trend.
- Mr. Bohorquez affirmed that the performance aspect of the report has been highly favorable in comparison to the budget. However, he also explained that there might be some challenges associated with the presumed fourth wave of COVID in the weeks to come. Dan Woods, CEO, added that the budget is submitted for regulatory reasons and that it would be unrealistic to assess the current financial performance to the budget. To get a better picture, they have been aligning current forecasts to the year prior, to account for and understand the true implications of COVID.

**Motion:** To approve FY21 Period 8 Financials.

Movant: Fung Second: Po

Ayes: Chen, Fung, Kliger, Miller, Po, Rebitzer, Somersille, Ting, Watters,

Zoglin **Noes:** None

FY21 Period 8 Financials were approved

|    |                                   | Abstentions: None Absent: None Recused: None  |                                       |
|----|-----------------------------------|---|---------------------------------------|
| 7. | GOVERNANCE<br>COMMITTEE<br>REPORT | a. Proposed Resolution 2021-04: Proposed Temporary<br>Suspension of El Camino Hospital Bylaws Article VIII. Section<br>8.3  | Resolution<br>2021-04 was<br>approved |
|    |                                   | Director Fung discussed the Governance Committee's recommendation to temporarily suspend the bylaw that requires that an officer shall not serve more than two consecutive terms for two years each as a chairperson. By allowing the temporary suspension, the current chairperson would serve for an additional year currently set to expire on June 30, 2021. Director Fung further explained that the purpose of this decision is to allow for continuity of the Board Leadership during COVID-19, and also to be able to implement the hospital's strategic plan, which is currently underway. |                                       |
|    |                                   | A brief discussion ensued regarding the strategic plan and timeline, succession plan for Board Leadership going forward, and further guidance from Attorney Colin Coffey.   |                                       |
|    |                                   | Mr. Coffey, Counsel from Best Best and Krieger Attorneys at Law, brought about that the current Board could not bind a future Board in the outcome of any forthcoming election.   |                                       |
|    |                                   | Chair Chen then clarified that the Board would have a standard election as required by the law.   |                                       |
|    |                                   | <b>Motion:</b> To approve Proposed Resolution 2021-04: Proposed Temporary Suspension of El Camino Hospital Bylaws Article VIII. Section 8.3   |                                       |
|    |                                   | Movant: Fung Second: Miller Ayes: Chen, Fung, Kliger, Miller, Po, Rebitzer, Somersille, Ting, Watters, Zoglin Noes: None Abstentions: None Absent: None Recused: None   |                                       |
|    |                                   | b. Proposed Revised Board Officer Nominations and Selection Procedures  |                                       |
|    |                                   | The Board engaged in a robust discussion about the selection procedures and processes for officer nominations. This included the benefits and setbacks of a paper vote, and a possible scenario in which three candidates for a given position could receive the same amount of votes.  | D                                     |
|    |                                   | <b>Motion:</b> To approve Proposed Revised Board Officer Nominations and Selection Procedures.  | Revised<br>Board<br>Officer           |
|    |                                   | Movant: Fung Second: Miller   | Nominatio ns and                      |
|    |                                   | Amendment: Zoglin   | Selection Procedures                  |
|    |                                   | To recommend change to a simultaneous paper vote with validation by a neutral party who reports the results.  | approved.                             |

| April 7, 2021   Page 4   | Movant: Director Fung accepted the amendment.   |   |
|--|---|---|
|  | Director Miller withdrew her second to the motion.  |   |
|  | Second: Kliger  |   |
|  | Ayes: Chen, Fung, Kliger, Po, Rebitzer, Somersille, Ting, Watters, Zoglin Noes: None Abstentions: Miller Absent: None Recused: None   |   |
|  | Further discussion ensued regarding the elimination of a candidate that receives the fewest votes. However, this suggestion was already reflected within the nominations and selection procedures; thus, no further amendments were necessary.  |   |
| 8. ADJOURN TO CLOSED SESSION                                   | Motion: To adjourn to closed session at 5:53pm pursuant to Gov't Code Section 54957.2 for approval of the Minutes of the Closed Session of the Hospital Board Meeting (03/10/2021); pursuant to Health and Safety Code Section 32155 for a report of the Medical Staff; deliberations concerning reports on Medical Staff quality assurance matters: Quality Committee Report (Medical Staff Credentials and Privileges Report, Quality Council Minutes); pursuant to Health and Safety Code Section 32155 for a report of the Medical Staff; deliberations concerning reports on Medical Staff quality assurance matters: Medical Staff Report; pursuant to Health and Safety Code Section 32106(b) for a report and discussion involving health care facility trade secrets: Strategic Planning Update; pursuant to Gov't Code Section 54956.9(d)(2) — conference with legal counsel — pending or threatened litigation and Gov't Code Section 54957 and 54957.6 for a discussion and report on personnel matters: CEO Report on Legal Services and Personnel Matters; and pursuant to Gov't Code Section 54957 for discussion and report on personnel performance matters — Senior Management: Executive Session.  Movant: Miller Second: Fung Ayes: Chen, Fung, Kliger, Po, Rebitzer, Somersille, Ting, Watters, Zoglin Noes: None Absent: None Recused: None | Adjourned<br>to closed<br>session at<br>5:53 pm |
| 9. AGENDA ITEM 15:<br>RECONVENE OPEN<br>SESSION/<br>REPORT OUT | Open session was reconvened at 8:05 pm by Vice-Chair Zoglin. Agenda Items 9-14 were addressed in closed session.  During the closed session, the Board approved the Minutes of the Closed Session of the Hospital Board Meeting (03/10/2021), Minutes of the Closed Session of the Executive Compensation Committee (11/5/2020), Quality Committee Report, including the Medical Staff Credentials and Privileges Report, and the Annual Summary of Physician Financials by a unanimous vote in favor of all members present and participating in the meeting (Directors Chen, Fung, Kliger, Miller, Po, Rebitzer, Somersille, Ting, and Zoglin).   |   |
| 10. AGENDA ITEM 16:<br>CONSENT<br>CALENDAR                     | Vice-Chair Zoglin asked if any member of the Board or the public wished to remove an item from the consent calendar. No items were removed.  Motion: To approve the consent calendar: Minutes of the Open Session of  | Consent<br>calendar<br>approved                 |

| April 7, 2021   Fage 3                   | the Hospital Board Meeting (03/10/2021); Revised FY21 Advisory Committee Assignments; Letter of Reasonableness; Executive Compensation Open Session Meeting Minutes (11/5/2020); FY21 Period 7 Financials; Urology Call Panel; Medical Staff Report; Finance Committee Approvals (Acute Rehab Professional Services Agreement and Community Benefits Grant). |                                    |
|--|--|------------------------------------|
|  | Movant: Fung Second: Watters Ayes: Fung, Kliger, Miller, Po, Rebitzer, Somersille, Ting, Watters, Zoglin Noes: None Abstentions: None Absent: Chen Recused: None   |                                    |
| 11. AGENDA ITEM 17:<br>CEO REPORT        | Dan Woods, CEO, reported on relaxed our visitor policy due to improving pandemic conditions, management efforts on Inclusion-Diversity, Equity, and Belonging, great results at our Annual Heart Forum, and ECH Los Gatos earned a spot on Newsweek's national Best Maternity Care Hospitals list for 2021.  |                                    |
| 12. AGENDA ITEM 15:<br>BOARD<br>COMMENTS | None.  |                                    |
| 13. AGENDA ITEM 16:<br>ADJOURNMENT       | Motion: To adjourn at 8:18 pm.  Movant: Miller Second: Po Ayes: Fung, Kliger, Miller, Po, Rebitzer, Somersille, Ting, Watters, Zoglin Noes: None Abstentions: None Absent: Chen Recused: None  | Meeting<br>adjourned at<br>8:18 pm |

Attest as to the approval of the foregoing minutes by the Board of Directors of El Camino Hospital:

| Lanhee Chen                   | Julia E. Miller                   |
|-------------------------------|-----------------------------------|
| Chair, ECH Board of Directors | Secretary, ECH Board of Directors |

Prepared by: Diksha Jagga, Contracts Admin/Governance Services EA



### Minutes of the Open Session of the Special Meeting to Conduct a Study Session of the **El Camino Hospital Board of Directors** Wednesday, April 14, 2021

Pursuant to State of California Executive Order N-29-20 dated March 18, 2020, El Camino Health did not provide a physical location for this meeting. Instead, the public was invited to join the open session meeting via teleconference.

**Others Present** 

**Lanhee Chen, Chair\*\*** Peter C. Fung, MD\*\* Julie Kliger, MPA, BSN\*\* Julia E. Miller, Secretary/Treasurer\*\* Jack Po, MD, PhD\*\*

\*\*via videoconference

**Members Absent** 

None

George O. Ting, MD\*\* **Don Watters\*\*** 

Carol A. Somersille, MD\*\*

**Members Present** 

**Bob Rebitzer\*\*** 

John Zoglin, Vice-Chair\*\*

| Ag | genda Item  | Comments/Discussion   |  |  |  |  |  |
|----|---|---|--|--|--|--|--|
| 1. | CALL TO ORDER   | Chair Chen called the closed session meeting of the El Camino Hospital Board of Directors to order at 5:31 pm. All Board members were present and participated via teleconference and videoconference pursuant to Santa Clara County's shelter in place order. A quorum was present pursuant to State of California Executive Orders N-25-20 dated March 12, 2020 and N-29-20 dated March 18, 2020. |  |  |  |  |  |
| 2. | CONFLICT OF INTEREST DISCLOSURES  Chair Chen asked if any of the Board members had a conflict of interest with any of the items on the agenda. None were reported.  Motion: to adjourn to alore a session at 5:33 pm. |   |  |  |  |  |  |
| 3. | ADOURN TO<br>CLOSED SESSION   | Motion: to adjourn to closed session at 5:33 pm.  Movant: Miller Second: Kliger Ayes: Chen, Fung, Kliger, Miller, Po, Rebitzer, Somersille, Ting, Watters, Zoglin Noes: None Abstentions: None Absent: None Recused: None   |  |  |  |  |  |
| 4. | AGENDA ITEM 7:<br>RECONVENE<br>OPEN<br>SESSION/REPORT<br>OUT  | Open session was reconvened at 7:24 pm by Chair Chen. Agenda Item 3-6 were addressed in closed session.  During the closed session, no actions were taken.  |  |  |  |  |  |
| 5. | AGENDA ITEM 8:<br>BOARD<br>COMMENT  | No comments were noted.   |  |  |  |  |  |
| 6. | AGENDA ITEM 9:<br>ADJOURNMENT   | Motion: to adjourn at 7:25 pm.  Movant: Miller Second: Po Ayes: Chen, Fung, Kliger, Miller, Po, Rebitzer, Somersille, Ting, Watters, Zoglin Noes: None Abstentions: None  |  |  |  |  |  |

Absent: None
Recused: None

### Attest as to the approval of the foregoing minutes by the Board of Directors of El Camino Hospital:

Lanhee Chen Julia E. Miller

Chair, ECH Board of Directors Secretary, ECH Board of Directors

Prepared by: Stephanie Iljin, Supervisor of Executive Administration





### Minutes of the Open Session of the Special Meeting to Conduct a Study Session of the El Camino Hospital Board of Directors Wednesday, April 28, 2021

Pursuant to State of California Executive Order N-29-20 dated March 18, 2020, El Camino Health did not provide a physical location for this meeting. Instead, the public was invited to join the open session meeting via teleconference.

Members Present
Lanhee Chen, Chair\*\*
Peter C. Fung, MD\*\*
Julie Kliger, MPA, BSN\*\*
Julia E. Miller, Secretary/Treasurer\*\*
Jack Po, MD, PhD\*\*
Bob Rebitzer\*\*
Carol A. Somersille, MD\*\*
George O. Ting, MD\*\*

Don Watters\*\*

John Zoglin, Vice-Chair\*\*

**Others Present** 

\*\*via videoconference

**Members Absent** 

None

| Ag | genda Item   | Comments/Discussion   |  |  |  |  |  |
|----|--|---|--|--|--|--|--|
| 1. | CALL TO ORDER  | Chair Chen called the closed session meeting of the El Camino Hospital Board of Directors to order at 5:31 pm. All Board members were present and participated via teleconference and videoconference pursuant to Santa Clara County's shelter in place order. A quorum was present pursuant to State of California Executive Orders N-25-20 dated March 12, 2020 and N-29-20 dated March 18, 2020. |  |  |  |  |  |
| 2. | POTENTIAL<br>CONFLICT OF<br>INTEREST<br>DISCLOSURES          | Chair Chen asked if any of the Board members had a conflict of interest with any of the items on the agenda. None were reported.  |  |  |  |  |  |
| 3. | ADOURN TO<br>CLOSED SESSION                                  | Motion: to adjourn to closed session at 5:33 pm.  Movant: Watters Second: Miller Ayes: Chen, Fung, Kliger, Miller, Po, Rebitzer, Somersille, Ting, Watters, Zoglin Noes: None Abstentions: None Absent: None Recused: None  |  |  |  |  |  |
|    | AGENDA ITEM 7:<br>RECONVENE<br>OPEN<br>SESSION/REPORT<br>OUT | Open session was reconvened at 7:00 pm by Chair Chen. Agenda Item 3-6 were addressed in closed session.  During the closed session, no actions were taken.  |  |  |  |  |  |
| 5. | AGENDA ITEM 8:<br>BOARD<br>COMMENT                           | No comments were noted.   |  |  |  |  |  |
| 6. | AGENDA ITEM 9:<br>ADJOURNMENT                                | Motion: to adjourn at 7:01 pm.  Movant: Miller Second: Watters Ayes: Chen, Fung, Kliger, Miller, Po, Rebitzer, Somersille, Ting, Watters, Zoglin Noes: None Abstentions: None   |  |  |  |  |  |

Absent: None
Recused: None

### Attest as to the approval of the foregoing minutes by the Board of Directors of El Camino Hospital:

Lanhee Chen Julia E. Miller

Chair, ECH Board of Directors Secretary, ECH Board of Directors

Prepared by: Stephanie Iljin, Supervisor of Executive Administration





### **Summary of Financial Operations**

Fiscal Year 2021 – Period 8 7/1/2020 to 02/28/2021

# Operational / Financial Results: Period 8 – February 2021 (as of 2/28/2021)

**PERIOD 8 - RESULTS** 

| (\$ thousands)    |                              | Current Year | Budget  | Variance to<br>Budget | Performance<br>to Budget | Prior Year | Variance to<br>Prior Year   | Variance to<br>Prior Year  |
|-------------------|------------------------------|--------------|---------|-----------------------|--------------------------|------------|---|--|
|                   | ADC                          | 229          | 237     | (8)                   | -3.3%                    | 259        | (31)  | (31) -11.8% (199) -10.5% (346) -11.3% (1,646) -31.0% 3,474 35.7% (11,312) -3.5%  (27) -0.9% 3.9 13.2% 1,641 10.3% (0.7) -1.3%  (1,170) -1.4% (2,546) -2.8% (4,499) -57.8% (3,443) -24.6% 38,274 -185.4% -4.8% -56.6% -3.4% -22.4%  |
|                   | Total Discharges             | 1,705        | 1,840   | (135)                 | -7.3%                    | 1,904      | (199)   |  |
| Activity / Volume | Adjusted Discharges          | 2,713        | 2,758   | (44)                  | -1.6%                    | 3,059      | (346)   | -11.3%   |
| Activity / Volume | Emergency Room               | 3,663        | 3,957   | (294)                 | -7.4%                    | 5,309      | Prior Year  259 (31) 1,904 (199) 3,059 (346) 5,309 (1,646) 9,739 3,474 5,932 (11,312) 2,894 (27) 29.6 3.9 5,887 1,641 52.0 (0.7) 6,443 (1,170) 1,172 (2,546) 7,783 (4,499) 4,023 (3,443) 0,641) 38,274 8.5% -4.8% | -31.0%   |
|                   | OP Procedural Cases          | 13,213       | 8,068   | 5,145                 | 63.8%                    | 9,739      | 3,474   | 35.7%  |
|                   | Gross Charges (\$)           | 314,620      | 294,152 | 20,468                | 7.0%                     | 325,932    | (11,312)  | -3.5%  |
|                   | Total FTEs                   | 2,868        | 2,795   | 72                    |                          | -0.9%      |   |  |
| Oneretions        | Productive Hrs. / APD        | 33.6         | 31.2    | 2.4                   | 7.6%                     | 29.6       | 3.9   | -3.5% (27) -0.9% 3.9 13.2% 641 10.3% (0.7) -1.3%   |
| Operations        | Cost Per Adjusted Discharge  | 17,528       | 17,147  | 381                   | 2.2%                     | 15,887     | 1,641   | 10.3%  |
|                   | Net Days in A/R              | 51.3         | 49.0    | 2.3                   | 4.7%                     | 52.0       | (0.7)   | -1.3%  |
|                   | Net Patient Revenue (\$)     | 85,273       | 74,702  | 10,571                | 14.2%                    | 86,443     | (1,170)   | -1.4%  |
|                   | Total Operating Revenue (\$) | 88,625       | 79,050  | 9,575                 | 12.1%                    | 91,172     | (2,546)   | Year         Prior Year           (31)         -11.8%           (199)         -10.5%           (346)         -11.3%           (1,646)         -31.0%           3,474         35.7%           11,312)         -3.5%           (27)         -0.9%           3.9         13.2%           1,641         10.3%           (0.7)         -1.3%           (1,170)         -1.4%           (2,546)         -2.8%           (4,499)         -57.8%           (3,443)         -24.6%           38,274         -185.4%           -4.8%         -56.6%           -3.4%         -22.4% |
|                   | Operating Income (\$)        | 3,285        | 243     | 3,042                 | 1252.4%                  | 7,783      | (4,499)   |  |
| Financial         | Operating EBIDA (\$)         | 10,580       | 6,763   | 3,817                 | 56.4%                    | 14,023     | (3,443)   | -24.6%   |
| Performance       | Net Income (\$)              | 17,633       | 1,755   | 15,878                | 904.6%                   | (20,641)   | 38,274  | 474     35.7%       312)     -3.5%       (27)     -0.9%       3.9     13.2%       641     10.3%       (0.7)     -1.3%       170)     -1.4%       546)     -2.8%       499)     -57.8%       443)     -24.6%       274     -185.4%       3.4%     -56.6%       3.4%     -22.4%  |
|                   | Operating Margin (%)         | 3.7%         | 0.3%    | 3.4%                  | 1106.3%                  | 8.5%       | -4.8%   | -56.6%   |
|                   | Operating EBIDA (%)          | 11.9%        | 8.6%    | 3.4%                  | 39.5%                    | 15.4%      | -3.4%   | -22.4%   |
|                   | DCOH (days)                  | 552          | 435     | 116                   | 26.7%                    | 452        | 100   | 22.1%  |

| Moody's | Performance |                    |
|---------|-------------|--------------------|
| 'A1'    | 'Aa3'       | to 'A1'<br>Medians |
|         |             |                    |
|         |             |                    |
|         |             |                    |
|         |             |                    |
|         |             |                    |
|         |             |                    |
|         |             |                    |
|         |             |                    |
|         |             |                    |
| 47.7    | 47.1        |                    |
| 106,723 | 257,000     |                    |
| 116,864 | 314,648     |                    |
| 3,948   | 10,135      |                    |
| 11,301  | 27,969      |                    |
| 8,219   | 18,726      |                    |
| 2.9%    | 3.6%        |                    |
| 9.7%    | 8.9%        |                    |
| 254     | 264         |                    |

Moody's Medians: Not-for-profit and public healthcare annual report; September 9, 2020. Dollar amounts have been adjusted to reflect month averages.



# Operational / Financial Results: YTD FY2021 (as of 2/28/2021)

### YTD FY2021 - RESULTS

| (\$ thousands)    | Current Year                 | Budget    | Variance to<br>Budget | Performance<br>to Budget | Prior Year | Variance to<br>Prior Year | Variance<br>Prior Ye |        |
|-------------------|------------------------------|-----------|-----------------------|--------------------------|------------|---------------------------|----------------------|--------|
|                   | ADC                          | 242       | 203                   | 40                       | 19.5%      | 240                       | 3                    | 1.1%   |
|                   | Total Discharges             | 14,985    | 13,846                | 1,139                    | 8.2%       | 16,347                    | (1,362)              | -8.3%  |
| Activity / Volume | Adjusted Discharges          | 22,993    | 20,697                | 2,295                    | 11.1%      | 25,578                    | (2,585)              | -10.1% |
| Activity / volume | Emergency Room               | 32,644    | 28,168                | 4,476                    | 15.9%      | 42,085                    | (9,441)              | -22.4% |
|                   | OP Procedural Cases          | 103,890   | 62,089                | 41,801                   | 67.3%      | 77,404                    | 26,486               | 34.2%  |
|                   | Gross Charges (\$)           | 2,756,191 | 2,197,973             | 558,217                  | 25.4%      | 2,603,852                 | 152,338              | 5.9%   |
|                   | Total FTEs                   | 2,811     | 2,836                 | (25)                     | -0.9%      | 2,802                     | 10                   | 0.3%   |
| 0                 | Productive Hrs. / APD        | 31.4      | 34.4                  | (3.0)                    | -8.8%      | 30.8                      | 0.6                  | 2.0%   |
| Operations        | Cost Per Adjusted Discharge  | 17,295    | 18,534                | (1,239)                  | -6.7%      | 15,806                    | 1,489                | 9.4%   |
|                   | Net Days in A/R              | 51.3      | 49.0                  | 2.3                      | 4.7%       | 52.0                      | (0.7)                | -1.3%  |
|                   | Net Patient Revenue (\$)     | 708,057   | 570,803               | 137,255                  | 24.0%      | 683,988                   | 24,069               | 3.5%   |
|                   | Total Operating Revenue (\$) | 739,167   | 607,998               | 131,169                  | 21.6%      | 720,831                   | 18,336               | 2.5%   |
|                   | Operating Income (\$)        | 39,107    | (32,128)              | 71,234                   | 221.7%     | 61,440                    | (22,333)             | -36.3% |
| Financial         | Operating EBIDA (\$)         | 95,900    | 21,613                | 74,288                   | 343.7%     | 101,595                   | (5,694)              | -5.6%  |
| Performance       | Net Income (\$)              | 195,122   | (9,957)               | 205,080                  | 2059.6%    | 85,901                    | 109,221              | 127.1% |
|                   | Operating Margin (%)         | 5.3%      | -5.3%                 | 10.6%                    | 200.1%     | 8.5%                      | -3.2%                | -37.9% |
|                   | Operating EBIDA (%)          | 13.0%     | 3.6%                  | 9.4%                     | 265.0%     | 14.1%                     | -1.1%                | -7.9%  |
|                   | DCOH (days)                  | 552       | 435                   | 116                      | 26.7%      | 452                       | 100                  | 22.1%  |

| Moody's | Moody's Medians |                    |  |  |  |  |  |  |
|---------|-----------------|--------------------|--|--|--|--|--|--|
| 'A1'    | 'Aa3'           | to 'A1'<br>Medians |  |  |  |  |  |  |
|         |                 |                    |  |  |  |  |  |  |
|         |                 |                    |  |  |  |  |  |  |
|         |                 |                    |  |  |  |  |  |  |
|         |                 |                    |  |  |  |  |  |  |
|         |                 |                    |  |  |  |  |  |  |
|         |                 |                    |  |  |  |  |  |  |
|         |                 |                    |  |  |  |  |  |  |
|         |                 |                    |  |  |  |  |  |  |
|         |                 |                    |  |  |  |  |  |  |
| 47.7    | 47.1            |                    |  |  |  |  |  |  |
| 853,780 | 2,055,999       |                    |  |  |  |  |  |  |
| 934,912 | 2,517,185       |                    |  |  |  |  |  |  |
| 31,587  | 81,076          |                    |  |  |  |  |  |  |
| 90,404  | 223,749         |                    |  |  |  |  |  |  |
| 65,748  | 149,807         |                    |  |  |  |  |  |  |
| 2.9%    | 3.6%            |                    |  |  |  |  |  |  |
| 9.7%    | 8.9%            |                    |  |  |  |  |  |  |
| 254     | 264             |                    |  |  |  |  |  |  |

Moody's Medians: Not-for-profit and public healthcare annual report; September 9, 2020. Dollar amounts have been adjusted to reflect 8 month totals.



# Financial Overview: Period 8 - February 2021

Period ending 2/28/2021

### **Financial Performance**

- February operating income was \$3.2M compared to a budgeted \$243K, resulting in a favorable variance of \$1M. The primary drivers are favorable outpatient activity and payer mix.
- February volumes were challenged, but revenues continue to be stronger than budget as demonstrated by:
  - <u>IP discharges</u> were unfavorable to budget by 60 cases / 4% and 179 cases / 11.1% lower than the same period last year while <u>Adjusted Discharges</u> (OP impact included) were unfavorable to budget by 44 cases / 1.6% and 346 cases / 11.3% lower than same period last year
  - Favorable variance gross charges of \$21.3M due primarily to inpatient services:
    - Inpatient gross charges: Favorable to budget by \$14M / 11% variance primarily driven by c
    - Cath lab, Operating Room, and Laboratory Services
  - Operating Expenses were unfavorable to budget by \$6.5M / 8.3%, primarily due to patient activity, increased use / cost of PPE associated with Covid-19 and other Covid-19 associated expenses
    - SWB were unfavorable by \$5.2M / 12%
    - Supplies were unfavorable by \$1.7M / 22%
    - All other discretionary non-volume driven expenses were favorable to budget by \$400K
    - Additional expenses attributed to Covid-19 have been \$1.2M per month for the first eight months of FY2021
- Non Operating Income includes:
  - Favorable variance of \$12.8M primarily due to unrealized gains on investments



# Financial Overview: Period 8 – February 2021 (cont.)

Period ending 2/28/2021

### **Financial Performance**

### **Hospital Operations:**

- Adjusted Discharges (AD): Unfavorable to budget by 44 ADs / 1.6% and below prior year by 346 ADs / 11%:
  - Mountain View: Unfavorable to budget by 97 ADs / 4.5% and below prior year by 358 ADs/ 14.6%
  - Los Gatos: Favorable to budget by 56 ADs / 10% and above than prior year by 8 ADs / 1%
  - Operating Expense Per <u>CMI Adjusted Discharge</u>: \$17,527 which is 2.2% unfavorable to budget
     Note: Excludes depreciation and interest

### El Camino Health Medical Network (ECHMN) Operations:

- February's total visits of 26,454 was 16% above prior month and 25.2% favorable to budget and included 7,972 COVID vaccination visits
- Net Income was unfavorable to budget by \$760K in February, but was \$661K favorable to February of 2020
- YTD February ECHMN Net Income is slightly unfavorable to budget by \$800K / 3.4%, but remains favorable to prior year by \$2.1M / 8.1%



# Financial Overview: YTD FY2021 (as of 2/28/2021)

### **Consolidated Financial Performance**

- YTD FY2021 net operating margin of \$39.1M compared to the budget of -\$32.1M
- Year-over-year operating margin is \$22.3M lower than the same period last year, which is
  primarily due to an increase in depreciation and interest of \$16.7M expenses associated with
  recently completed capital projects at the Mountain View campus
- Strong volume recovery from the first wave of Covid-19, continues to be the primary driver of favorable performance to budget
  - Adjusted discharges are 2,295 /11% favorable to budget and 2,585 / 10.1% lower than the same period last year
- Operating expenses are \$59.9M / 9.4% unfavorable to budget
  - Unfavorability driven higher than budgeted volumes and expenses associated with Covid-19 pandemic
  - Operating expense per <u>CMI adjusted discharge</u> of \$17,295 is 6% favorable to budget which demonstrates consistent management of variable expenses

Note: Excludes depreciation and interest expense



# **Consolidated Statement of Operations (\$000s)**

**Period ending 02/28/2021** 

| Period 8  | Period 8  | Period 8    | Variance    |         |                                | YTD         | YTD         | YTD         | Variance    |           |
|-----------|-----------|-------------|-------------|---------|--------------------------------|-------------|-------------|-------------|-------------|-----------|
| FY 2020   | FY 2021   | Budget 2021 | Fav (Unfav) | Var%    | \$000s                         | FY 2020     | FY 2021     | Budget 2021 | Fav (Unfav) | Var%      |
|           |           |             |             |         | OPERATING REVENUE              |             |             |             |             | _         |
| 325,932   | 314,620   | 294,152     | 20,468      | 7.0%    | <b>Gross Revenue</b>           | 2,603,852   | 2,756,191   | 2,197,973   | 558,217     | 25.4%     |
| (239,489) | (229,347) | (219,450)   | (9,897)     | (4.5%)  | Deductions                     | (1,919,864) | (2,048,133) | (1,627,171) | (420,963)   | (25.9%)   |
| 86,443    | 85,273    | 74,702      | 10,571      | 14.2%   | <b>Net Patient Revenue</b>     | 683,988     | 708,057     | 570,803     | 137,255     | 24.0%     |
| 4,729     | 3,352     | 4,348       | (996)       | (22.9%) | Other Operating Revenue        | 36,843      | 31,110      | 37,196      | (6,086)     | (16.4%)   |
| 91,172    | 88,625    | 79,050      | 9,575       | 12.1%   | <b>Total Operating Revenue</b> | 720,831     | 739,167     | 607,998     | 131,169     | 21.6%     |
|           |           |             |             |         | OPERATING EXPENSE              |             |             |             |             |           |
| 46,497    | 48,592    | 43,397      | (5,195)     | (12.0%) | Salaries & Wages               | 369,822     | 389,591     | 353,670     | (35,921)    | (10.2%)   |
| 12,903    | 13,587    | 11,392      | (2,195)     | (19.3%) | Supplies                       | 106,240     | 111,641     | 88,249      | (23,392)    | (26.5%)   |
| 14,080    | 14,770    | 13,927      | (843)       | (6.1%)  | Fees & Purchased Services      | 113,084     | 114,109     | 115,015     | 907         | 0.8%      |
| 3,669     | 1,097     | 3,571       | 2,474       | 69.3%   | Other Operating Expense        | 30,090      | 27,926      | 29,451      | 1,526       | 5.2%      |
| 1,458     | 1,392     | 916         | (477)       | (52.1%) | Interest                       | 4,227       | 11,392      | 7,396       | (3,997)     | (54.0%)   |
| 4,781     | 5,903     | 5,605       | (298)       | (5.3%)  | Depreciation                   | 35,928      | 45,402      | 46,345      | 943         | 2.0%      |
| 83,388    | 85,341    | 78,807      | (6,534)     | (8.3%)  | <b>Total Operating Expense</b> | 659,391     | 700,060     | 640,126     | (59,934)    | (9.4%)    |
| 7,783     | 3,285     | 243         | 3,042       | 1252.4% | <b>Net Operating Margin</b>    | 61,440      | 39,107      | (32,128)    | 71,234      | (221.7%)  |
| (28,424)  | 14,349    | 1,512       | 12,836      | 848.7%  | Non Operating Income           | 24,461      | 156,016     | 22,170      | 133,845     | 603.7%    |
| (20,641)  | 17,633    | 1,755       | 15,878      | 904.6%  | Net Margin                     | 85,901      | 195,122     | (9,957)     | 205,080     | (2059.6%) |
| 14,023    | 10,580    | 6,763       | 3,817       | 56.4%   | Operating EBIDA                | 101,595     | 95,900      | 21,613      | 74,288      | 343.7%    |
|           |           | ·-          |             |         |                                |             |             |             | •           |           |
| 15.4%     | 11.9%     | 8.6%        | 3.4%        |         | <b>Operating EBIDA Margin</b>  | 14.1%       | 13.0%       | 3.6%        | 9.4%        |           |
| 8.5%      | 3.7%      | 0.3%        | 3.4%        |         | <b>Operating Margin</b>        | 8.5%        | 5.3%        | -5.3%       | 10.6%       |           |
| -22.6%    | 19.9%     | 2.2%        | 17.7%       |         | Net Margin                     | 11.9%       | 26.4%       | -1.6%       | 28.0%       |           |






# **APPENDIX**



# **YTD FY2021 Financial KPIs – Monthly Trends**





# **Investment Scorecard (as of 12/31/2020)**

| Key Performance Indicator                  | Status | El Camino               | Benchmark                   | El Camino                | Benchmark | El Camino                             | Benchmark            | FY21 Budget | Expectation Per<br>Asset Allocation |
|--|--------|-------------------------|-----------------------------|--------------------------|-----------|---------------------------------------|----------------------|-------------|-------------------------------------|
| Investment Performance                     |        | CY 4Q 2020 / FY 2Q 2021 |                             | Fiscal Year-to-Date 2021 |           | 8y 2m Since Inception<br>(annualized) |                      | FY 2021     | 2019                                |
| Surplus cash balance*                      |        | \$1,302.1               |                             | -                        |           |                                       |                      | -           | -                                   |
| Surplus cash return                        |        | 8.5%                    | 8.0%                        | 13.0%                    | 12.2%     | 6.6%                                  | 6.4%                 | 4.0%        | 5.6%                                |
| Cash balance plan balance (millions)       |        | \$336.2                 |                             | -                        |           |                                       |                      |             | -                                   |
| Cash balance plan return                   |        | 11.2%                   | 9.2%                        | 17.1%                    | 14.3%     | 8.9%                                  | 7.9%                 | 6.0%        | 6.0%                                |
| 403(b) plan balance (millions)**           |        | \$581.5                 |                             | -                        |           |                                       |                      |             | -                                   |
| Risk vs. Return                            |        | 3-y                     | /ear                        |                          |           |                                       | ce Inception alized) |             | 2019                                |
| Surplus cash Sharpe ratio                  |        | 0.69                    | 0.67                        |                          |           | 0.93                                  | 0.93                 |             | 0.34                                |
| Net of fee return                          |        | 7.8%                    | 7.3%                        | -                        |           | 6.6%                                  | 6.4%                 |             | 5.6%                                |
| Standard deviation                         |        | 9.0%                    | 8.6%                        | -                        |           | 6.3%                                  | 6.1%                 |             | 8.7%                                |
| Cash balance Sharpe ratio                  |        | 0.73                    | 0.64                        | -                        |           | 1.00                                  | 0.96                 | -           | 0.32                                |
| Net of fee return                          |        | 9.8%                    | 8.0%                        | -                        |           | 8.9%                                  | 7.9%                 | -           | 6.0%                                |
| Standard deviation                         |        | 11.4%                   | 10.3%                       | -                        |           | 8.1%                                  | 7.4%                 | -           | 10.3%                               |
| Asset Allocation CY 4Q 2020 / FY 2Q 2021   |        |                         |                             |                          |           |                                       |                      |             |                                     |
| Surplus cash absolute variances to target  |        | 9.4%                    | < 10% Green<br>< 20% Yellow | -                        |           |                                       |                      | -           |                                     |
| Cash balance absolute variances to target  |        | 7.9%                    | < 10% Green<br>< 20% Yellow | -                        |           |                                       |                      | -           |                                     |
| Manager Compliance CY 4Q 2020 / FY 2Q 2021 |        |                         |                             |                          |           |                                       |                      |             |                                     |
| Surplus cash manager flags                 |        | 16                      | < 24 Green<br>< 30 Yellow   |                          |           |                                       |                      |             | -                                   |
| Cash balance plan manager flags            |        | 19                      | < 27 Green<br>< 34 Yellow   | -                        |           |                                       |                      | -           | -                                   |

<sup>\*</sup>Excludes debt reserve funds (~\$12 mm), District assets (~\$34 mm), and balance sheet cash not in investable portfolio (\$214 mm). Includes Foundation (~\$39 mm) and Concern (~\$15 mm) assets. \*\*As of September 30, 2020 as more recent data not yet available.





© 2021 Mercer LLC. All rights reserved.



# YTD FY2021 and January Operating Margin, Non-Operating Income and Net Margin by Affiliate (as of 2/28/2021) (\$ in thousands)

|  | Period 8- Month |         |          | Period 8- FYTD |          |          |
|--|-----------------|---------|----------|----------------|----------|----------|
|  | Actual          | Budget  | Variance | Actual         | Budget   | Variance |
| El Camino Hospital Operating Margin              |                 |         |          |                |          |          |
| Mountain View                                    | 443             | 678     | (235)    | 41,383         | (18,135) | 59,518   |
| Los Gatos  | 5,777           | 2,006   | 3,771    | 23,341         | 11,571   | 11,770   |
| Sub Total - El Camino Hospital, excl. Afflilates | 6,220           | 2,685   | 3,536    | 64,724         | (6,565)  | 71,289   |
| Operating Margin %                               | 7.5%            | 3.7%    |          | 9.2%           | -1.2%    |          |
| El Camino Hospital Non Operating Income          |                 |         |          |                |          |          |
| Sub Total - Non Operating Income                 | 13,099          | 1,207   | 11,892   | 150,506        | 19,744   | 130,762  |
| El Camino Hospital Net Margin                    | 19,319          | 3,892   | 15,427   | 215,230        | 13,180   | 202,051  |
| ECH Net Margin %                                 | 23.2%           | 5.3%    |          | 30.7%          | 2.3%     |          |
| Concern  | 21              | 54      | (32)     | 288            | 248      | 40       |
| ECSC   | 0               | 0       | 0        | (3)            | 0        | (3)      |
| Foundation                                       | 1,276           | 33      | 1,243    | 3,795          | 3        | 3,792    |
| El Camino Health Medical Network                 | (2,983)         | (2,223) | (760)    | (24,188)       | (23,388) | (800)    |
| Net Margin Hospital Affiliates                   | (1,686)         | (2,137) | 451      | (20,108)       | (23,137) | 3,029    |
| Total Net Margin Hospital & Affiliates           | 17,633          | 1,755   | 15,878   | 195,122        | (9,957)  | 205,080  |





### EL CAMINO HOSPITAL BOARD OF DIRECTORS BOARD MEETING MEMO

**To:** El Camino Hospital Board of Directors

**From:** Apurva Marfatia, MD, Enterprise Chief of Staff

Michael Kan, MD Chief of Staff Los Gatos

**Date:** May 12, 2021

**Subject:** Medical Staff Report – Open Session

### **Recommendation:**

To approve the Medical Staff Report, including Policies and Procedures identified in the attached list and the Delineation of Privileges.

### **Summary:**

- 1. Situation: The Medical Executive Committee met on April 22, 2021
- **2.** Background: MEC received the following informational reports.
  - Quality Council The Quality Council met on April 7, 2021. Reports and performance dashboards were reviewed and approved from the following ECH Departments/Service Lines:
    - 1. Annual PI Report
    - 2. Imaging Services Quality Dashboard
    - 3. Information Flow QA-PI-PS Plan 2021
    - 4. Quality Council Reporting Calendar
    - 5. Patient and Employee Safety Dashboard FY21
    - 6. Org Goals and Quality FY21
    - 7. Quarterly Board Quality Dashboard
    - 8. Registries List for PI-PS
    - 9. External Regulatory Compliance Indicators
    - 10. Direct Clinical Care Contract Report CY2020
  - b) Leadership Council The Leadership Council met on April 13, 2021 and discussed the following:
    - 1. Credentials Committee Update
    - 2. Financial Update
    - 3. Medical Staff Services Update
    - 4. ER and ICU Handoff
    - 5. Department of Medicine Update
    - 6. Palliative Care Update
    - 7. CME Update
  - c) The COO Report was provided and included the following updates:
    - 1. Introduction; Kalpana Nathan, MD Chief Medical Director of Mental Health and Addiction Services
    - 2. Procedural Report Update
    - 3. Varian Halcyon Ethos Update
    - 4. Epic "On My Way" Application
    - 5. ED Volumes
    - 6. Women's Hospital Expansion

- d) The CMO Report was provided and included the following updates:
  - 1. Enterprise Quality Dashboard
  - 2. Top Readmission Reasons
  - 3. COVID Update
  - 4. Hospital-acquired Pneumonia Team
  - 5. ERAS Team Update
  - 6. Surgical Site Infection Update
  - 7. Safety Event Breakdown
  - 8. Leapfrog Scores
  - 9. CMS Star Rating
- e) The CNO Report was provided and included the following updates:
  - 10. COVID+ Patient Placement Changes
  - 11. New Graduate RN Residency Cohort and Transition Program
  - 12. Nurses Week May 6<sup>th</sup> to May 12<sup>th</sup>

**<u>List of Attachments</u>**: Policies and Procedures

**Suggested Board Discussion Questions:** None



### OPEN SESSION CEO Report May 12, 2021 Dan Woods, CEO

### **Operations**

ECH received final approval from The Joint Commission for new performance measures for its disease-specific certification programs in Hip Replacement, Knee Replacement, Hip Fracture, and Spine Fusion as part of its renewal. This approval signified the final step in the successful biennial re-certification of the six programs across the enterprise. Notably, the hip and knee programs received zero improvement findings.

El Camino Health's Radiation Oncology department became the first location in California to treat a patient with Adaptive Intelligence (AI) using ETHOS on April 14. We are only the fifth hospital to have ETHOS in the nation and first in California. Ethos uses Artificial intelligence for imaging and treatment planning. During treatment, Ethos enables the therapist to access diagnostic quality MR, PET, and CT images and make real-time adjustments to treatment.

ECH Los Gatos performed lateral spine fusion without a patient repositioning utilizing an advanced surgical technique and latest technology. The advanced surgical approach to reach the front of the spine allows for the time savings of approximately one hour of operative time under anesthesia, which is beneficial to patients. This advanced approach is a first performed in the Bay Area.

### **Nursing Services**

To honor the great contribution of all our nurses for Nurses Week in May (the American Nurse Association has designated the whole month of May to honor nurses). El Camino Health plans to have a special day on May 13 to commemorate and recognize the contribution of nursing. LeAnn Thieman, an international nurse speaker and author of "Chicken Soup for the Nurses Soul," will visit with the nursing staff and provide an uplifting presentation on that day.

### **Ambulatory Care (Silicon Valley Medical Development – SVMD)**

Since January, El Camino Health has administered more than 32,000 doses of the Pfizer and Moderna vaccines to community members. We are working closely with community benefit organizations to vaccinate underserved and technically challenged populations. There are dedicated appointment slots to accommodate these community members. The First Street Vaccine Clinic has been closed and vaccination operations have been consolidated at the Maude Avenue/LinkedIn site and they are administering more than 500 a day.

### **Quality and Safety**

Fortune IBM/Watson 100 Top hospitals in the U.S. announced this week that El Camino Health's hospital was named the only hospital in California to qualify for this prestigious award. A total of 20 hospitals in the large community hospital category were named. This award is based on an analysis of clinical outcomes, extended outcomes, operational efficiency, patient experience, financial health, and for the first time ever community support. In addition, 20 of the 100 top hospitals were named as Everest Award winners and El Camino Health's hospital was one of them. This Everest Award distinguishes El Camino Health not only as a top performing hospital but also a rapidly improving hospital, which is a recognition of sustained, high performance at all levels of the organization.



#### **Finance**

The FY22 budget is in a finalization process. It will continue our path to full recovery from the pandemic and will be presented for approval at the joint FC/ECHB Board meeting on May 24.

### **Human Resources**

The Hospital's new CNA Apprenticeship Program graduated its first four apprentices from EVS, Nutrition and Administrative support roles who will transfer into their new jobs as certified nursing assistants in April. Recruiting is underway for the next class that will begin in late summer to support continued opportunities for growth for entry-level staff. Additionally, Labor & Delivery is welcoming six ECH nurses into their 12-week transition program, an experiential learning program to become a Labor and Delivery Nurse.

### **Information Services**

El Camino Health integrated into the BlueShield "MyTurn" state vaccine program scheduling system to enable patients to conveniently schedule vaccines. A new EPIC tool was enabled called "On My Way" to allow patients to notify the ED of their symptoms and share an estimated time of arrival. This allows the ED staff to prepare for the patient prior to arrival.

### **Marketing and Communications**

With consumer attitudes around delaying care continuing, the "Return to Health" brand advertising campaign was extended another month to run through May. As vaccine supply became available and ECH opened its mass vaccination site, a new vaccine advertising campaign started on April 26 and will continue to the end of May to support county and state efforts to reach all consumers, including those who are reluctant to get the vaccine, to sign-up and get the vaccine. Service line search engine marketing (SEM) and primary care campaigns continue in market.

### Philanthropy

Through April 2021, the El Camino Health Foundation has raised \$2.73M in new gifts and commitments, which is 34% of our total annual goal. Individual gifts and benefit event opportunities have been limited during the pandemic. Despite these challenges, we have added 14 new donors at the level of \$10,000 and above. In addition, we have been able to generate a budget savings of nearly \$750,000. Our base donor group remains strong, with our annual gift programs on pace to reach our fiscal year goal of \$650,000. The donor renewal rate has surpassed 51% towards a goal of 60%.

The Foundation secured a \$50,000 gift from a LinkedIn executive, a new donor, for the high-volume vaccination clinic in Sunnyvale, with a particular interest in removing barriers for the underserved. The donor has lined up a \$15,000 corporate matching gift and plans to share information about the philanthropic opportunity with other executives and the company's employee giving program.

A total of \$50,000 from the COVID-19 Emergency Response Fund was allocated to purchase prescription safety goggles for hospital employees. Moreover, the Hope to Health's \$30,000 grant to the Women's Imaging Center improved the patient experience with relaxing music and video art in the waiting and exam rooms.



### **Corporate, Government & Community Health Services**

### Concern

Concern is on target with new business revenue and account retention. Business challenges include workload with many complex RFPs and significant effort on our technology roadmap. In addition, Concern launched a new mindfulness solution with integrated suite of services on its digital platform.

### South Asian Heart Center (SAHC) and Chinese Health Initiative (CHI)

The SAHC started its second STOP Diabetes prevention program, signed up new AIM to Prevent Program participants, and hosted eight community and corporate online workshops with 410 event attendees.

With a generous donation from Peter Fung, MD, CHI launched the monthly "Ask the Expert" column in the World Journal, the largest Chinese newspaper in North America. The half-page column features reliable information from medical professionals, describes health conditions that disproportionately impact the Chinese community, and showcases ECH enterprise services.

### **Government & Community Relations**

El Camino Health hosted State Senator Josh Becker as well as Santa Clara County Supervisor Otto Lee for tours of the community COVID-19 vaccination clinic in Sunnyvale. We partnered with Community Benefit on equity collaborations to help vaccinate the underserved. Sunnyvale Community Services and Community Services Agency of Mountain View, Los Altos & Los Altos Hills have been making vaccination appointments for their clients at the Sunnyvale clinic.

A student career panel for the Mountain View Los Altos Union High School District AVID program was organized to provide educational equity to our traditionally underrepresented high school students. Many of the students are the first to go to college and are diverse. All of the students are on track to attend four-year colleges, and many are interested in health careers. An El Camino Health affiliated physician, nurse leader, HR director, clinical psychologist, and imaging services leader shared their career journeys and answered student questions on March 31.

### **Auxiliary**

The Auxiliary donated 371 volunteer hours for the month of March.